Impact of globalisation and trade liberalisation on the Indian industry : a case analysis of the Indian pharmaceutical industry. by Vishwajit, Vibha.
IMPACT OF GLOBALISATION AND TRADE
LIBERALISATiION ON ~HE INDIAN INDUSTRY: A CASE
ANALYSIS OF q"HE INDIAN PW~RMACEUTICAL
INDUSTRY
Vibha Vishwajit
Supervisor: Prof Elza T
Submitted in partial fulfillment of the requirements for
the degree of
MASTER OF S(JS ESS ADMINISTRATION
UNIVERStTY OF NATAL
The Graduate School of Business, Faeulf¥:of Managetnenf
University 0 Natal (Durban)
DECLARATION
This research has not been previously accepted for any degree and is not





I wish to express my sincere thanks to people who have provided assistance, guidance
and support during the course of this study. In particular I would like to thank the
following:
1) My supervisor Professor Elza Thomson, for her supervision and guidance
throughout the study
2) Professor M.Williamson, for his guidance during the course of the study
3) Lastly and most importantly, my parents and sister for their patience,
continuous support and encouragement throughout the course of the study
111
ABSTRACT
The study is designed to carry out the impact of trade liberalization and globalisation
on the Indian industry with the help of a case analysis of the Indian pharmaceutical
industry. The study is broken down into five chapters in order to carry out the process
of the study systematically. The first chapter presents the background, motivation and
the value of the study. Focus of chapter two, the literature review, which helps in
brining out aspects associated with trade liberalisation and globalisation. Chapter
three provides an overview of the Indian pharmaceutical industry with references to
the global industry. An analysis of the industry against the literature developed in
chapter two will be the focus of chapter four. Lastly, chapter 5 is designed to
formulate recommendations for the industry, incorporating government's role.
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Autarky: A condition of self-sufficiency. Specifically, it is a national policy of
economic independence.
Bulk Drugs: Bulk drugs are medically effective chemicals, derived from four
types of raw materials, namely, plant derivatives, animal derivatives,
synthetic chemicals and biogenetic derivatives (human insulin).
Consumer Surplus: Consumer surplus measures the difference between
what a person is willing to pay for a good and the amount he/she actually is
required to pay.
Drug Price Control Order: DPCO controls the domestic prices of major
bulk drugs and their formulations with an aim to provide patients with
medicines at affordable prices. DPCO ascertains, as per Drug Policy
guidelines, the bulk drugs (and their formulations) to be kept under price
control.
Foreign Exchange Regulations Act, 1973: An Act to consolidate and
amend the law regulating certain payments, dealings in foreign exchange
and securities, transactions indirectly affecting foreign exchange and the
import and export of currency, for the conservation of the foreign exchange
resources of the country and the proper utilisation thereof in the interests of
the economic development of the country.
Foreign Direct Investment Direct investment in business operations in a.
foreign country (includes both direct investment and portfolio investment).
General Agreement on Tariffs and Trade: International treaty that
committed signatories to lowering tariff and non-tariff barriers to the free
flows of goods across national borders and led to the WTO.
Generic Drug: When a medicine is first developed, the company
discovering it is afforded a period of patent protection, usually 10-15 years.
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Only the innovator can manufacture and market the medicine. However,
when the patent expires, other companies can market an equivalent product
under its chemical, or generic name.
Gini Coefficient The Gini coefficient is a number between zero and one
that measures the degree of inequality in the distribution of income in a
given society. The coefficient would register zero inequality (0.0 =minimum
inequality) for a society in which each member received exactly the same
income and it would register a coefficient of one (1.0 = maximum inequality)
if one member got all the income and the rest got nothing.
Gross Domestic Product: GDP is the gross domestic product or the
income of the economy, C stands for consumption expenditure, I for
investment expenditure, G for government spending, and X-M for exports
minus imports.
Mean Deviation: refers to the percentage difference between the income of
a randomly selected individual and average income across the world.
The Monopolistic and Restrictive Trade Practices Act, 1969: It was first
enacted to was enacted, to ensure that the operation of the economic
system does not result in the concentration of economic power in hands of
few, to provide for the control of monopolies, and to prohibit monopolistic
and restrictive trade practices in India.
Producer surplus: producer surplus measures the welfare of a group of
firms who sell a particular product at a particular price. Producer surplus is
defined as the difference between what producers actually receive when
selling a product and the amount they would be willing to accept for a unit of
the good.
World Trade Organisation: The World Trade Organisation (WTO) is the
global international organisation dealing with the rules and regulations of
trade between nations and an organisation that succeeded the General
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Agreement on Tariffs and Trade (GATT) as a result of the successful
completion of the Uruguay round of GATT negotiations.
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To the surprise of many, although not widely recognised, the global village
has arrived. Against the fractured world of early 1980s, truncated into three
divergent power and economic blocs, the world at the beginning of the new
millennium is marching fast towards a new era, not only in time-scale but
reaching out to a new techno-economic rendezvous-of free flow of capital,
product and process technology, expertise and knowledge. Whilst almost all
segments are registering technological thrust, the twin marvels,
telecommunications and information technology, have completely repainted
the canvas. Thanks to the Internet, representing the technological
matrimony, it is no longer possible for any society to remain shrunk in a shell
of national markets which remained highly protected until the conclusion of
the global milestone of the World Trade Organization (WTO) agreements
and Uruguay Round of trade negotiations.
Every day it can be heard in the news, through academicians, businesses
students, and people on the streets, read in the textbooks, and in every
single instance the word globalisation seems to bring out either a very
skeptic view or indicate how globalisation has helped nations reach the
milestones of growth and prosperity.
So, what is globalisation, why is it criticised and what are the reasons for its
support?
Globalisation is different things to different people and thus affects
individuals, nations, and businesses differently.
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The aspect of globalisation that has been taken into consideration for the
purpose of this study is the effect of outward looking policies across nations
and its effect on industries within the economy and across nation.
Recent attacks on the globalisation have also translated into attacks on the
wisdom of outward-oriented trade policies that the developing countries
have embraced with increasing frequency. Skeptics question the ability of
liberal trade policies in order to stimulate growth, development and
economic prosperity. In addition, they also blame growth failure on the surge
of imports from increased openness. Moreover, the outward-oriented trade
policies are viewed as detrimental with regards to national sovereignty,
employment and poverty.
An alternative view suggests that trade liberalisation and globalisation are
responsible for cross border economic interdependence and integration of
economies of the world. Globalisation has also acted as a catalyst in
opening national boarders to trade, capital, technology and information.
Altogether this has resulted in increased trade and robust growth in the
foreign direct investment through transnational and multinational
organisations.
Arguments put forward by both, protagonists and the skeptics seem
convincing, however, which argument holds true remains to be seen. As far
as developing countries are concerned, there is compelling evidence that
openness is a necessary condition for rapid growth. Evidence also shows
that there are few developing countries that have grown rapidly on a
sustained basis without simultaneously experiencing rapid growth in their
exports and imports.
It is amazing that some countries have failed to experience economic
growth and development even after adopting outward oriented policies?
This and more will become clear as the study unfolds.
Chapter 1
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1,2 BACKGROUND OF THE RESEARCH
According to Uma Kapila (2001) and Reserve Bank of India, since
independence (that is since 1947), India has largely remained a closed
economy with its emphasis on producing everything domestically and as a
consequence of its adoption of the protectionist policies. India, in the last 10-
15 years has witnessed a transition from closed to an open economy, solely
as an outcome of globalisation and WTO policies. This has led to the
increased foreign trade and inflow of foreign investment (See fig 1.1 for FDI
trends).
The inward looking policies implemented by India until 1991, has acted as
protection for domestic firms. However, due to Uruguay round of trade
negotiations and WTO policies, India has established various trade
liberalisation policies, making the entry of foreign firms easier. It is evident
that due to this aspect the domestic firms are facing immense competition
from multinational organizations. For long run survival, the domestic firms
will have to change their strategic planning. It is evident that strategic
alliances such as mergers, acquisitions and joint ventures will be the order
of the day in this given scenario.
At present India's economic policies are designed to attract significant
capital inflows into India on a sustained basis and to encourage technology
collaboration between Indian and foreign firms. Economic policy, especially
of the nineties, has removed several constraints on economic growth. India
has sought to increase inflows of Foreign Direct Investment (see fig 1.1)
with much liberal policies since 1991, after forty years of cautious attitude
towards it. Progressive liberal policies adopted in this regard have led to
increasing inflows of foreign investment in the country, both in terms of
direct investment, as well as portfolio investment (Reserve Bank of India:
2002) Figure 1.1 provides with an illustration of foreign investment inflows
into India during the years 1991-2002 (both direct investment and portfolio
investment). The new export import policies are more liberal in nature, which
Chapter 1
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facilitate, economic growth and development. Rationalised tariff levels and
removal of quantitative restrictions characterises the current trade policy.
The immediate objective of India as per the EXIM (export and import) policy,
announced on 31 st march 2001, is to achieve at least 1 percent share of
global trade by 2004 (Kumar; 2000)
Foreign Investment Inflows in India (in Us$ million)
Years
Figure 1.1: Foreign Investment Inflows in India (Us$ Million)
Source: Reserve Bank of India
With the advent of globalisation and hence trade liberalisation, entry of
foreign firms has increased the competition for domestic firms. As a result of
this competition, local organisations have been reviewing their strategic
planning. Industries such as food, textile, automobile and pharmaceutical all
have been affected by foreign competition. Therefore, the domestic firms will
have to review their strategies in order to stay competitive.
1..a..MOTIYATION FOR THE RESEARCH
The Indian pharmaceutical industry is one of the most developing industries
in India, with increasing exports and imports. Prior to 1970 the Indian
pharmaceutical industry experienced the tide of liberalisation when it was
Chaoter 1
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still in its infantile stages of development. However, in 1970, the government
adopted a protectionist policy in order to protect its infant industries.
Now, once again the domestic pharmaceutical industry will have to face the
same situation as it did prior to 1970.
Multinational pharmaceutical companies were responsible for giving the
Indian domestic industry a run for its money prior to 1970. Now that the
winds of liberalisation have caught India, the international industry has once
again moved their attention towards India. However, due to the nature of the
industry and sustained growth and development over the last three
decades, the Indian industry has emerged as one of the most competitive
pharmaceutical players across the globe. Therefore, it remains to be seen
what liberalisation and the competition has in store for the domestic industry
and India.
This research is undertaken for the above-mentioned reasons, i.e. to
evaluate the impact of trade liberalisation and globalisation Indian
pharmaceutical industry
..u VALUE OF THE PROJECT
This study will help formulate recommendations for the Indian
pharmaceutical companies which will assist them reassess and re-evaluate
their strategies in the light of globalisation, assisting them gain a competitive
edge. This study will also highlight the role for the government, which would
help India in achieving prosperity, economic growth and development, social
welfare and all that globalisation promises.
liPROBLEM STATEMENT
Impact of trade liberalisation and globalisation on the Indian industry: A case
analysis of the Indian pharmaceutical industry. The study will also explore
the impact of trade liberalisation and globalisation.
Chapter 1
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1,6 OBJECTIVES OF THE STUDY
To evaluate: -
The impact of trade liberalisation and globalisation.
To determine: -
The effect of trade liberalisation and globalisation on the Indian
pharmaceutical industry.
To establish:
Recommendations and suggestions for the long-term survival and
development of the indigenous pharmaceutical industry and
government's role to help achieve the objectives of sustained
growth, prosperity and overall development.
UBESEARCH METHODOLOGY
The research is fundamentally qualitative. However, it will involve the
collection of data through the use of secondary sources and case studies.
1,7,1 CASE ANALYSIS
Due to the qualitative nature of the research, the methodology used to carry
out this dissertation will be case analysis. The information will be obtained
through multiple sources of information such as textbooks, journals, Internet
etc. A case analysis of the Indian pharmaceutical industry will be undertaken
in order to assess the impact of globalisation on domestic companies.
Analysis of competition from foreign players, strategic alliances, and its
effect on inflow of capital, employment, poverty and economic growth will be
analysed.
1&J-IMITATIONS OF THE PROJECT
No interaction with the pharmaceutical companies, since they weren't
prepared to provide information and therefore had to, primarily, rely
on the Internet and secondary sources of information.
Chapter 1
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With a broad topic of this genre, which tries to cover aspects of an
industry and an economy, might leave certain aspects uncovered.
Due to the nature of the study, it was not possible to evaluate more
than one industry. However, the pharmaceutical industry might not be
truly indicative of all the industries because there are several other
factors affecting industries across the economy.
1.9 RESEARCH SCHEPULE
Table 1.1 presents the research schedule. The study will commence with
the proposal, collection of data, which will include observing the markets in
India and collection of data through all possible sources, data analysis and
finally the write up of the report.
Research Schedule
·nLAC~iYity:~:"_" _I Ti~" frQm~ __
I ~ ; DIssertation proposal.. . _I OCT 2002 - NOV 2002
Ii Data and Information Collection IJANUARY 2003 -FEB 2003
LJ[Data ~nal:is _ _ 1 MAR 2003 -_APRIL ~003.DI Final Write Up APRIL 2003 - JUNE 2003
Table 1.1: Research Schedule
-
I
1.1 0 STRUCTURE OF THE STUDY
The study will be carried out in the form of five chapters; the first chapter will
layout the proposal of the study, indicating aspects such as the background,
methodology and the value of the study. The remaining four chapters will
Chapter 1
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carry out the study in systematic manner. The outline of the chapters that
make up the study is presented below: -
Chapter Two: Literature Review
Chapter two will covers the theoretical aspects relating to the
trade liberalisation and globalisation. International trade theories
and models, such as Mercantilism, Absolute Advantage,
Comparative Advantage, Hecksher-Ohlin, and Porters Diamond
will be discussed to understand the implications of trade and
removal of trade barriers. In addition, effects of tariff will also be
discussed. Porters diamond, which more or less incorporates all
the other models and theories, will be used for the case analysis
in chapter 4. Globalisation and related issues such as poverty,
national sovereignty, employment, growth and development will
be discussed and analysed. Finally, a discussion of the impact of
foreign competition due to opening up of borders will be
undertaken.
Chapter Three: Overview of the Pharmaceutical Industry
A detailed overview of the Indian pharmaceutical industry will be
presented in this section. The history, structure of the Indian
pharmaceutical industry, global industry structure, how does the
Indian industry compare with the global industry, what products
and services it provides, will be discussed.
Chapter Four: Analysis of the Pharmaceutical Industry
This chapter will evaluate the Indian pharmaceutical industry
against the information developed in chapter three and the
"models" established in chapter two.
Chapter 1
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Chapter Five: Recommendations and Conclusion
Recommendations for the pharmaceutical companies in order for
the industry to survive the winds of liberalisation and help in
making India a global industrial base will be formulated in this
chapter. Areas where the industry has a competitive edge will be
highlighted. In conjunction with this, certain recommendations for
the government will also be presented so as to achieve sustained
growth and development.
1Jj SUMMARY
The study is designed to carry out an analysis of the Indian pharmaceutical
industry exploring the impact of trade liberalisation and globalisation. There
are many speculations as far as the topic of 'globalisation' is concerned.
That is why most economies are reluctant to liberalise. It is strongly felt that
globalisation brings with it, poverty, unemployment, and loss of national
sovereignty. Whether this is just a speculation, or there is some reality in it,
is hard to evaluate, but an attempt will be made to at least try and explore
the reality. Lets begin by looking at the impact of trade liberalisation and
globalisation and related issues such as poverty, national sovereignty,
employment, growth and development.
Chapter 1 Tntt'(')rh.r+in~'j;
CHAPTER TWO: IMPACT OF TRADE LIBERALISATION AND
GLOBALlSATION: LITERATURE REVIEW
2.1 INTRODUCTION
What happens when autarkic approaches such as, import substitution
behind high tariff walls fail to provide sustainable growth and development?
Well, to answer this question lets look at a simple economic formula: -
GDP =C + I + G + (X-M)
Which implies higher (X-M) will lead to higher GDP (Schiller: 2000:31-32).
In other words, increase in foreign trade that is exports and imports will lead
to high levels of gross domestic product or the income of the economy.
Kautilya further supports this argument; according to him trade is the third
pillar of economic prosperity (Sindhwani: 2003). Kautilya stated, as cited by
Sindhwani (2003), ''The three principle components of national economics
and prosperity are 'krishi' (agriculture), 'pashupalaya' (cattle tending) and
'vanijya' (trade). So, does it imply that, higher trade = higher growth and
prosperity? In that case every country must implement this simple economic
formula and reach the targets of growth and development? However, this is
not the picture that emerges in real life. So, where does the problem lie?
Maybe it lies in what happens after trade? Then, what is the impact of trade
on nation and more importantly what is the outcome of much talked about
globalisation? Lets try and analyse some of the aspects related to trade
liberalisation.
According to the theory, some degree of outward orientation is vital in order
to achieve sustainable growth, development, and poverty reduction. This
illustrates the underlying factor behind the rapid growth of the world
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been driven both by technological development and more importantly,
reduction in trade and investment barriers. Most of the developing countries
have adopted liberal policies to take full advantage of the opportunities for
economic development through trade.
Therefore, the solution to any country's problem with regard to growth and
development ought to be trade liberalisation and globalisation.
Unfortunately, according to the skeptics view, whereas on one hand,
liberalisation and globalisation have acted as a catalyst for growth, they
believe globalisation and trade liberalisation have not turned the tide against
poverty (Joseph Sliglitz: 2003). In fact the gap between rich and poor
countries and wealth disparities within countries have increased, indicating
that the rich have become richer while the poor have become poorer (Surjit
Bhalla: 2003).
Consequently, a fundamental question needs to be addressed, that is,
whether the shift towards a more integrated and interdependent global
economy has acted as an engine for growth or has it led to rise in
unemployment and poverty? And what is the affect of trade liberalisation on
national sovereignty, Job loss, labour exploitation and environment effects?
Micro economic questions also need to be addressed such as the impact of
trade liberalisation and globalisation on the domestic industry/ firms and
multinational organisations.
2.2 TRADE THEORIES
In order to better understand the implications of trade and removal of both
tariff and non-tariff barriers to trade, it will be worthwhile to look at some of
the international trade theories developed by great economists such as
Ricardo, Adam Smith, Michael Porters and David Hume. International trade
theories examine what trade patterns would evolve if trade were allowed to
move freely among countries and how much, in which product and with
whom a country will trade in absence of restrictions among nations. In
addition, the theories take into account governmental influence with the free
Chapter Two Literature Review
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movement of goods and services among countries in order to alter the
amount, composition and direction of trade (Sindhwani: 2003). In an attempt
to realise how international trade increases the welfare of its citizens, the
principles of Mercantilism, Absolute Advantage, Comparative Advantage
and Heckscher-Ohlin and Porters Diamond will be considered.
2.2.1 MERCANTILISM
Mercantilism theory of trade emerged in the 16th century and is one of the
first economic doctrines on international trade. The theory is based on the
idea that national wealth and power are best served by maintaining a trade
surplus, that is exporting more than importing. As Hill puts it, "its principle
assertion was that gold and silver were the mainstay of national wealth and
essential to vigorous commerce" (Hill: 2003: 142). During this time period
gold, silver and other precious metals were the currency of foreign trade and
therefore by maintaining trade surplus would accumulate gold, silver and
other precious metals and consequently increase its national wealth and
political control. Therefore, the aim of the government was to limit imports
and to facilitate exports. In order to achieve this, imports were discouraged
by tariffs, quotas etc and exports were encouraged by government in the
form of subsidies. The belief that trade surplus leads to economic growth
and development explains why until recently very many countries around
the globe have adopted an import substitution and protectionist policies.
The theory of mercantilism, which encourages countries to hide under the
blanket of trade barriers in order to dampen imports and stimulate exports,
provides no explanation for why these countries have failed to achieve
economic growth and development.
David Hume tried to analyse the weakness of the theory. According to him,
if China was trading with Japan and had a trade surplus, the resulting inflow
of capital would boost the money supply and generate inflation in China.
Consequently, in Japan, the outflow of capital would deflate the money
supply causing deflation leading to lower prices. This would, in turn
encourage the Japanese to buy fewer Chinese goods, as they are now
more expensive, and would encourage the Chinese to buy more from Japan
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since their goods are becoming cheaper. Thus the trade balance of Japan
would recover and China's trade balance would get worse. Therefore
according to Hume, no country can sustain a trade surplus. (Sindhwani
2003)
2.2.2 ABSOLUTE ADVANTAGE
A country has an absolute advantage over it's trading partners if it is able to
produce more of goods or services with the same amount of resources or
the same amount of goods or services with fewer resources (Schiller:
2000:712). Taking an example of Zambia, which has an absolute advantage
over many countries in the production of copper. This occurs because of the
existence of reserves of copper ore or bauxite. China has an absolute
advantage in the production of textile due to its low labour costs.
It can be clearly seen that in terms of the production of goods, there are
obvious gains from specialisation and trade. If Zambia produces copper and
exports it to China and imports textiles, both the countries would gain from
trade by specialising. This further can be ascertained with the use of the
production possibility curves of China and Zambia, which will help in
assessing the extent of gain from trade.
Absolute Advantage. Example of China and Zambia
20 Zambia 20 China
.... .... 15






20 0 5 10 15 20
Textiles Textiles
Figure 2.1: Absolute Advantage, Example of China and Zambia
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Gains from Trade for China and Zambia
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Table 2.1: Gains from Trade for China and Zambia
Figure 2.1 and table 2.1 helps to illustrate gains from trade and
specialisation. It is apparent that countries gain from trade; output of both
textile and copper is greater than before and therefore consumers of both
China and Zambia will be able to consume more. Table 2.1 shows how
consumption in both the countries have gone up relatively as a result of
specialisation and trade.
2.2.3 COMPARATIVE ADVANTAGE
What happens if countries like United States or Japan have an absolute
advantage in producing all the goods? Does it indicate that they will not
benefit from international trade since they can produce all the goods
efficiently at home?
According to Ricardo's theory (Sindhwani: 2003), a country has a
comparative advantage in the production of goods or services that it
produces at a lower opportunity cost than its trading partners. Some
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countries have an absolute advantage in the production of many good
s
relative to their trading partners. Others have an absolute disadvantage
,
which implies that, they are inefficient in producing all goods and service
s,
relative to their trading partners. The theory of comparative advantag
e
according to Ricardo argues that, put simply, it is better for a country that
is
inefficient at producing goods to specialise in the production of that good it
is
least inefficient at, compared with producing other goods (Jones: 2000).
US and China
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Figure 2.2: Comparative Advantage for China and U.S
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Table 2.2: Gains from Trade for US and China
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It can thus be derived that after U.S. and China exploit their comparative
advantage, in copper and textiles respectively, production of output
increases (which can be seen in the table 2.2). Since both the countries are
producing more, they can now engage in trade and benefit from it. Thus
consumption of copper and textiles increases in both the countries as a
result of specialisation and trade.
The essence of the theory is that 'potential world production is greater with
unrestricted free trade than it is with restricted trade' (Hill: 2003: 146).
Therefore it can be concluded that unrestricted trade is beneficial for
countries across the globe, but the degree to how much each nation actually
benefits might differ since model includes many unrealistic assumptions
(Jones: 2000): -
There are no transportion costs.
Costs are constant and there are no economies of scale.
There are only two economies producing two goods.
The theory assumes that traded goods are homogeneous
Factors of production are assumed to be perfectly mobile.
There are no tariffs or other trade barriers.
There is perfect knowledge, so that all buyers and sellers know
where the cheapest goods can be found internationally.
An important Question that arises is that, can this model be applied to the
real world scenario, which consists of numerous goods, high transportation
costs, volatile exchange rates, immobile resources/factors of production and
dynamic environment? Is it realistic to conclude that free trade is mutually
beneficial for all the nations across the world? Recent studies undertaken by
Sindhwani and the like, suggest that even though the model has
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shortcomings, countries can benefit from free trade, which will be analysed
using real world examples later in the chapter.
2.2.4 HECKSCHER-OHLlN THEORY
Ricardo's model is based on differences between countries in technology
and puts emphasis on the fact that comparative advantage arises from
differences in productivity. The Eli Hecksher and Bertil Ohlin theory (1933)
as cited by Sindhwani (2003) of factor endowment is based on differences in
relative factor endowments across countries and differences between goods
in their factor intensity (the proportion in which factors are used). Which
means the extent to which a country is enriched in resources such as, land
labour, or capital (Internet 1). Therefore a country with abundant labour will
have a low labour cost and will export goods that are labour intensive.
Countries such as China, India, Malaysia, Indonesia are endowed with
unskilled labour that is why these developing countries produce more of
goods that are labour intensive, such as textiles, footwear and agricultural
products and the like. On the other hand countries such as, Germany,
Japan, United States, excel in the production and export goods which are
skilled labour intensive or capital intensive, such as, computer software,
automobile, aircrafts etc.
An example of a two-country trade case, Japan and Malaysia, where one is
enriched with skilled labour and the other is endowed with unskilled labour
respectively will assist in understanding the outcome of trade.
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Table 2.3: Illustration of Hecksher Ohlin Theory using examples of Japan and
Malaysia
Since Japan is skilled labour abundant country it will export automobile,
which provides it with a comparative advantage over Malaysia. Malaysia will
export textiles and import automobile from Japan. As trade opens up it
results in factor-Price equalisation, which claims that trade leads to
equalisation of returns to factors across countries.
Hence with trade, wages should become equal across countries and the
returns to other factors such as land and capital. If this holds true, then why
aren't wages in Japan, equal to wages in China, Malaysia or India?
However, wages and prices across the world paint a different picture
altogether. Why is it so? In order to answer this question it is important to
understand that the strong conclusion we derive from this model depends
on assumptions of, no trade restrictions, no transportation cost,
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homogeneous technology and uniform purchasing power across countries.
These assumptions make the models of international trade theory less
applicable to the real world. Nevertheless, they indicate a very fundamental
aspect that trade without any restrictions will eventually enhance the growth
performance of a country.
2.2.5 PORTERS DIAMOND
Michele Porter established Porters Diamond in an attempt to determine why
some nations archive international success in a particular industry while
others fail in international competition. Why does China do so well in the
textile industry? And Japan in the automobile industry? According to porters,
the theory that we have established so far, answers only a part of the
explanation.
According to Porter (Svend: 2001), four broad attributes of a nation shape
the environment in which homegrown firms compete and these attributes
promote or impede the creation of competitive advantage (see fig 2.3).











Figure 2.3: Determinant of National Competitive Advantage: Porter's Diamond
(Source: Svend: 2001)
Factor endowment, demand conditions, relating and supporting industries,
firm strategy, structure and rivalry are the four attributes that constitute the
diamond. According to Porters, firms are most likely to succeed in industries
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where the diamond is most favorable. He also stated that, " the diamond is
mutually reinforcing system" (Hill: 2003:159). The four attributes are
interlinked and the effect of one aspect spills over on to the others. For
instance, Porters states (Hill: 2003) that, ''favorable demand conditions will
not result in competitive advantage unless the state of rivalry is sufficient to
cause firms to respond to them".
In addition to this, according to him two very important variables such as
chance and government also play a very essential role in influencing
national demand. For example, innovation of the cell phones reshaped the
entire telecommunications industries and provided opportunity for nation's
firms to succeed over others. Similarly, government policies and regulations
can improve national advantage or can do the total opposite.
It is interesting to see how all the theories have some weaknesses but still
bring out a very important aspect, which can be of great importance in the
real world scenario. All the models signify the relevance of trade and how
countries across the world can benefit if they engage in trade, by
specialising, by capitalising on their factor endowments or by realising
where their comparative advantages lie.
2,3 THE EFFECT OF TARIFF ON TRADE
At this point it becomes essential to look at the effect of tariff since, our goal
is to try and assess how the liberalisation of trade helps or impedes the
development and economic growth of a country. It is argued that tariff not
only lowers world welfare but also the welfare of nations imposing these
tariffs. In addition to this, it is also believed that nations can achieve
something better without the imposition of tariffs as compared to what they
can achieve through the imposition of tariff (Pugel: 2000).
Simple supply and demand diagrams help to illustrate the welfare effects of
tariffs on producers, consumers and the nation as a whole. This will help in
order to evaluate whether the arguments by the trade protestors hold true.
For example, they claim trade rules are biased toward the interests of
producers.
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2.3.1 SMALL COUNTRY SCENARIO
The small country scenario means that the country's imports are a very
small share of the world market, so small, that even a complete elimination
of imports would have an imperceptible effect upon world demand for the
product and thus would not affect the world price. Thus, when a small
country implements a tariff, there is no effect upon the world price (Hill:
2003).
Lets consider a market in a small importing country such as Belgium that
faces an international or world price of Pw in free trade for rice (figure 2.4).
At Pw, domestic demand is Ow, domestic supply is Sw and imports equal to
the difference between Ow and Sw (See figure 2.4).







Sw ST DT Dw Quantity
Figure 2.4: Tariff effect on Belgium, a 'small' country case
When a specific tariff is implemented by Belgium (a small country) it will
raise the domestic price by the full value of the tariff. Consequently, the
price in the Belgium rises to PT as a result of the imposition of tariff. In this
case the tariff rate would be, PT - Pw (see fig 2.4).
2.3.1.1 TARIFF EFFECTS ON IMPORTING COUNTRY CONSUMERS
Consumers of the product in the importing country are worse-off as a result
of the tariff. The increase in the domestic price of both imported goods and
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the domestic substitutes reduces consumer surplus in the market. Which
can be seen in the figure 2.4, where loss of consumer surplus equals
A+B+C+D (Pugel: 2000).
2.3.1.2 TARIFF EFFECTS ON IMPORTING COUNTRY PRODUCER
Producers in the importing country are better off as a result of the tariff. The
increase in the price of their product increases producer surplus in the
industry (+A in figure 2.4). The increase in price also induces an increase in
output of existing firms (and perhaps the addition of new firms), an increase
in employment, and an increase in profit and/or payments to fixed costs.
2.3.1.3 TARIFF EFFECTS ON IMPORTING COUNTRY GOVERNMENT
The government receives tariff revenue as a result of the tariff (+C in figure
2.4). Who will benefit from the revenue depends on how the government
spends it. These funds help support diverse government spending
programs, therefore, someone within the country will be the likely recipient
of these benefits.
2.3.1.4 TARIFF EFFECTS ON NATIONAL WELFARE
The aggregate welfare effect for the country is found by summing the gains
and losses to consumers, producers and the government. The net effect
consists of two components: a negative production efficiency loss (B in
figure 2.4), and a negative consumption efficiency loss (0 in figure 2.4). The
two losses together are typically referred to as 'deadweight losses'. Since,
there are only negative elements in the national welfare change, the net
national welfare effect of a tariff must be negative. This means that a tariff
implemented by a "small" importing country will eventually result in reduced
national welfare.
Therefore it can be concluded that whenever a "small" country implements a
tariff, national welfare falls and the higher the tariff, the larger will be the loss
in national welfare. In addition, the tariff causes a redistribution of income.
Producers and the recipients of government spending gain, while
consumers lose. Due to the fact that the country is assumed "small," the
tariff has no effect upon the price in the rest of the world. Therefore there
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are no welfare changes for producers or consumers around the globe. Even
though imports are reduced, the related reduction in exports by the rest of
the world is assumed to be too small to have a noticeable impact.
2.3.2 LARGE COUNTRY SCENARIO
Lets assume that there are only two trading countries, one importing 'large
country' and one exporting country. The supply and demand curves for the
two countries are shown in figure 2.5. Pw is the free trade equilibrium price.
At that price, the excess demand by the importing country equals excess
supply by the exporter.









Figure 2.5: Large Country case
Sx Dx
Quantity
The quantity of imports and exports is shown as the green line segment on
each country's graph. When a large importing country implements a tariff it
will cause an increase in the price of the good on the domestic market and a
decrease in the price in the rest of the world. Suppose, after the tariff, the
price in the importing country rises to PM and the price in the exporting
country falls to px. If the tariff is a specific tax then the tariff rate would be
equal to the difference between PM and Px (Figure 2.5).
2.3.2.1 IMPACT OF TARIFF ON CONSUMERS
Consumers in the importing country suffer a reduction in welfare as a result




the domestic substitutes reduces the amount of consumer surplus in the
market, equivalent to the area A+S+C+D (Figure 2.5).
Consumers in the exporting country experience an increase in welfare as a
result of the tariff. The decrease in their domestic price raises the amount of
consumer surplus (+e see figure 2. 5) in the market.
2.3.2.2 IMPACT OF TARIFF ON PRODUCERS
Producers in the importing country experience an increase in welfare as a
result of the tariff, producer surplus increases by the area A (in figure 2.5).
The increase in the price of their product on the domestic market increases
producer surplus in the industry. The price increases also induces an
increase in output of existing firms and perhaps the addition of new firms,
increase in employment, and increase in profit.
Producers in the exporting country experience a decrease in welfare due to
tariff. The decrease in the price of their product in their own market reduces
producer surplus in the industry equivalent to the area e,f,g,h in figure 2.5.
Decline in price also induces a reduction in output, employment, and in profit
and payments to fixed costs.
2.3.2.3 IMPACT OF TARIFF ON GOVERNMENT REVENUE
The government receives revenue as a result of the tariff. Who benefits from
the revenue depends on how the government spends it. Typically the
revenue is simply included as part of the general funds collected by the
government from various sources. In this case it is impossible to identify
precisely who benefits. However, these funds help support many
government spending programs, which presumably helps most people in the
country, as is the case with public goods. Thus, someone within the country
is the likely recipient of these benefits.
2.3.2.4 IMPACT OF TARIFF ON NATIONAL WELFARE
The aggregate welfare effect for the country is found by summing the gains
and losses to consumers, producers and the government. The net effect on
importing country consists of three components: a positive terms of trade
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effect (G in figure 2.5), a negative production distortion (8 in figure 2.5), and
a negative consumption distortion (0 in figure 2.5).
For the reason that there are both positive and negative elements, the net
national welfare effect can be either positive or negative. The interesting
result, however, is that it might be positive. This means that a tariff
implemented by a "large" importing country may raise national welfare.
The aggregate welfare effect for the exporting country is found by summing
the gains and losses to consumers and producers. The net effect consists of
three components: a negative terms of trade effect (g in figure 2.5), a
negative consumption distortion (f in figure 2.5), and a negative production
distortion (h in figure 2.5).
Since all three components are negative, the importer's tariff must result in a
reduction in national welfare for the exporting country. However, it is
important to note that a redistribution of income occurs, i.e., some groups
gain while others lose. In this case the sum of the losses exceeds the sum
of the gains.
Usually, if a "large" country implements a small tariff, it will elevate national
welfare but if the tariff is set too high, national welfare will fall. One important
thing to remember is that there will be a positive optimal tariff that will
maximise national welfare.
However, it is also important to note that everyone's welfare does not rise
when there is an increase in national welfare. Instead there is a
redistribution of income. Producers of the product and recipients of
government spending will benefit, but consumers might end up loosing. A
national welfare increase implies that the sum of the gains exceeds the sum
of the losses across all individuals in the economy. Economists generally
argue that, in this case, compensation from winners to losers can potentially
alleviate the redistribution problem.
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2.3.2.5 TARIFF EFFECTS ON WORLD WELFARE
The effect on world welfare is found by summing the national welfare effects
in the importing and exporting countries. By noting that the terms of trade
gain to the importer is equal to the terms of trade loss to the exporter, the
world welfare effect reduces to four components: the importer's negative
production distortion (B in figure 2.5), the importer's negative consumption
distortion (0 in figure 2.5), the exporter's negative consumption distortion (f
in figure 2.5), and the exporter's negative production distortion (h in figure
2.5). Since each of these is negative, the world welfare effect of the import
tariff is negative. The sum of the losses in the world exceeds the sum of the
gains. It can be concluded that an import tariff results in a reduction in world
production and consumption efficiency. In other words trade liberalisation
increases production and consumption efficiency and therefore national
welfare.
Protecting industries through tariffs is costly on consumers. World Bank
Reports (Internet 3) established that, consumers pay, on average, $155,000
for every job "saved" in a protected industry. At the same time, such
protectionist measures harm economies by diverting resources away from
the most productive sectors. For example, in United States, steel tariffs raise
the cost of steel, harming automobile manufacturers and other steel
consuming industries, which employ 10 times as many workers as the steel
manufacturers. These productive sectors of the economy also benefit when
trade opens new markets across the globe for their products. Expanding
trade means more output, which in turn leads to employing more workers.
Consequently, liberalisation of trade and elimination of tariffs lead to
increased employment, lower prices leading to growth and development in
the long run.
Even though many tariff barriers have been flagged in the last few decades,
leading to a more integrated world, countries continue to use many
mechanisms to restrict imports. Non-tariff barriers such as quotas,
Chapter Two literature Review
27 of 88
embargoes, administrative delays, licenses and economies of scale still
remain (Joseph Stiglitz: 2003).
What happens if these barriers are imposed? What happens to domestic
production? What happens to equilibrium price? What is the effect on
consumers and producers?
Quotas, a form of trade barriers is a physical limit imposed upon the amount
of a good that may be imported. They have the effect of restricting the total
supply to the domestic market. In addition, they also have the effect of
raising prices higher than they would otherwise be in the home country if
free trade was permitted (Sindhwani: 2003). They enhance the market
shares of "protected" domestic producers and limit the volume of goods and
services exported into the country from foreign production. Prohibitive tariffs
and non-tariff barriers can preclude and eliminate imports of some products
altogether.
Trade barriers are the natural consequence of self-interest and political
influence. Domestic producers and their workers tend to favour trade
barriers as a shield against foreign competition or in order to protect infant
industry. Consumers and society can benefit from free trade and suffer from
protectionism. In addition, at present many of the trade barriers are the
legacy of post WWII economics literature that recommended, "import
substitution" as a dynamic trade strategy for developing countries (Internet
1). Trade barriers were especially favoured for manufactured products, so
that less developed countries could create their own industrial sector and
emulate the historical experience of the industrialised economies.
2.&.jMPLlCATION FOR INDUSTRY
The essence of globalisation lies in the industries within a country since they
are affected the most. An industry generally has to alter its strategies in
order to remain competitive. Globalisation along with other things brings with
it, competition, which at times can be crucial for companies to improve their
quality, standard and efficacy. Global competition also calls for evaluation of
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strategic planning and encourages strategic alliances across companies
(Hisrich and Peters: 2000).
2.5.1 COMPETITION
As indicated by Sindhwani (2003), a line of reasoning, which emerges from
the economic restructuring in terms of liberalisation, is increase in
competition in the given industry stemming from both national and
international players. Without a doubt, domestic and external competition is
likely to grow and escalate where the producers chase the buyers and not
the other way around, which has been very evident in the past two-three
decades in the world economy. Liberalisation in foreign investment, abolition
of import licenses, de-licensing of the industries, and eradication of other
such barriers are likely to lead to more competition relative to 'pre-Iiberalised
era', stemming from both domestic industry as well as foreign industry. This
is a major impact of deregulation and a key characteristic of a freer economy
with all its pressures for efficiency and its pain of transition. Today industries
across the world can expect that the day of the sellers market, which
prevailed under the licensing regime, is by and large over and the day of the
consumer has arrived. This is, of course, of great advantage to the
consumer, and producers for purpose of achieving long-term
competitiveness of industries.
2.5.2 STRATEGIC ALLIANCES
With the globalisation of the world economy, companies are growing by,
strategic alliances to contain costs and stay competitive. Pressure on prices
has made Multinational Companies (MNCs) to resort to joint ventures,
mergers and acquisitions and other forms of strategic alliances in order to
contain cost and enhance research and development. Joint ventures and
other forms of strategic alliances have occurred between U.S and foreign
firms in order to penetrate international markets and have been a good
mechanism for a company to enter an international market. The last few
decades has witnessed strategic alliances between rival companies such as
General Motors and Toyota or General Electric and Westinghouse (Hisrich
and Peters: 2000: 532). Another example of alliance between Boeing,
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Mitsubishi, Fuji, and Kawasaki shows how businesses enter into strategic
alliances with the intention of sharing technology and cutting costs.
Strategic alliance may take any form of business organisation, which allows
resource pooling and cost sharing with the organisations involved. Alliances
may have the following advantages (refer to figure 2.6): -
Market Penetration
Makes marker penetration easier for both domestic and
multinational firms. For example, a joint venture allows a
multinational to enter the local market and at the same time allows
domestic firm to penetrate the foreign markets (Sindhwani: 2003).
Knowledge of Market information
For example, the local partner will be valuable in providing
knowledge of local markets and influence governments and other
institutions, which affect the business.
Production Facility
The availability of production facilities of the domestic partner
helps to minimise the problems associated with starting a new
production unit.
Capital Resources
Providing smaller firms who have limited financial resources with
an opportunity to gain access to capital and foreign investment.
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Access to new technologies
Increased brand power
Overall operational synergy
Greater cooperation through increased awareness of each other
Figure 2.6: A conceptual framework for strategic Alliances
(Source: Sindhwani: 2003)
2.6 OVERVIEW Of GLOBALlSATION
Globalisation is a process of increasing interconnectedness of individuals,
groups, companies and countries. Over the past 2 decades, foreign trade
and the cross-border movement of technology, labour, goods, ideas and
capital have been substantial. The technological, economic and political
changes have not only brought people closer together but have also
generated serious concerns over the terms of that integration. These
concerns have been generated by the realisation that while globalisation
has led to benefits for some, it has not led to benefits for all.
According to the international trade theory (as discussed before),
globalisation should equalise factor prices across countries. Due to trade in
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goods, services, and capital mobility, labor wages should equalise in
advanced and developing countries. If this holds true, then globalisation
should have been beneficial to workers and consumers in developing
countries. Unfortunately, globalisation has coincided with higher
unemployment, poverty in some areas and widening income inequality.
Therefore, is it correct to say that perhaps globalisation is responsible for
these trends despite of what the international theorists argue?
For some, all the commotion about the negative impact of globalisation on
workers and employment is just a disguise to support protectionist policy,
and to introduce new blockage to the free flow of goods, services and
capital across countries.
2.6.1.GLOBALlSATION DEBATE
Before jumping to any conclusion regarding globalisation and liberalisation
regime, it will be interesting to look at some of the arguments in favour of
and against globalisation
2.6.1. 1 PRO-GLOBALlSATION
The growth in trade between nations has contributed to lifting 3
billion people out of poverty over the past 50 years. Reducing
tariff barriers, which makes it easier for nations to trade with each
other, lifts the wealth of all nations by allowing them to
concentrate on those areas where they have greatest expertise
(Internet 19).
The Poor countries that have adopted a liberalisation regime have
in fact gained increases in employment and national income due
to labour and capital shifts from import-competing industries to
expanding, newly competitive export industries. In addition to
providing jobs, companies moving to developing countries often
export higher wages and working conditions compared with those
in domestic companies operating in the country. The experience
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in countries like Korea is that as countries develop, their wage
levels rise and the focus shifts from labour intensive to more
capital and knowledge intensive industries (Internet 1).
It is true that there has been some contraction in employment in
labour intensive industries such as textiles and footwear in
developed countries over the past 20 years as production has
moved to countries where labour is cheaper (Internet 3). However
this is part of the process of development. It would be
condemning less developed countries to even greater poverty to
restrict their ability to compete in industries like textiles in
developed markets.
2.6. 1.2 ANTI-GLOBALlSATION
Critics of globalisation say that rising inequality is the inevitable
consequence of market forces, which give the rich the power to add further
to their wealth. Hence, large corporations invest in poor countries only
because it enables them to make greater profits from low wage levels and
access to their (poor country's) natural resources (Joseph Sliglitz: 2003). It
is believed that the free market does nothing to address re-distribution of
wealth. It presumes that wealth will spill over to the poor.
Globalisation results in the exploitation of millions of workers in
countries that do not give workers rights to organise. For example,
a woman who sows a $200 Liz Claiborne jacket sown in El
Salvador is paid just 74 cents - less than half of one per cent. In
the US, the labour cost to sew a garment is typically 10 per cent of
the retail price (Internet 19).
Workers in poor countries may have to work 12 hours a day,
seven days a week with few protections for health and safety. In
some countries, globalisation leads to the exploitation of child,
and prison labour (Internet 3).
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Goods produced in developing countries under conditions
highlighted above undermine those produced in the industrialised
nations. The result has been a call for 'fair trade', as opposed to
'free trade'.
Within richer countries, there is growing inequality as unfair
competition from countries repressing workers' rights to organise
pushes down the earnings of the less skilled sections of the
workforce.
It is believed and mentioned by Joseph Stiglitz (2003) that, the
WTO is interested in defending intellectual property and investors'
rights, but not those of workers.
2aZ..j:FFECT OF LIBERALISATION AND GLOBALlSATION ON WAGES
International trade theories suggests that trade affects the prices of goods in
both exporting and importing countries. Which in turn affects the wages
(which is the price of labour) within countries by influencing the demand for
labour. Changes in prices of goods due to competition from imports alters
the profit prospects facing the firms. They in turn respond by shifting
resources away from loss-making sectors towards industries in which
profitability has gone up. Trade flows, thus, bring about shifts in the demand
for labour, as additional workers are required in newly profitable sectors and
fewer in loss-making sectors. If the supply of labour is fixed, changes in
demand will bring about a rise in wages, given that workers will demand a
premium for switching into more profitable industries.
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Figure 2.7: Wages and Openness to Trade
(Source: Martin Rama 2003)
International trade theories suggests that competition generated from
imports lowers the price of products (such as apparel and footwear) made
by unskilled labour relative to the price of products (such as computers and
software) made by skilled labour, so that domestic firms shift toward
production of skill-intensive goods. However, does the prices of goods in the
developed countries exhibit this? If the answer is yes, then trade might have
contributed to rising income inequality, but it must first be shown that
changes in product prices are the result of trade rather than other purely





























Table 2.4: Post 1980 Globalisers
(Source: Dollar and Kraay: 2000)
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A great deal of research has been undertaken by WTO and the World Bank
on this issue, and although the conclusions are not robust, there appears to
be little evidence of larger price increases in skilled-labour-intensive
products in advanced countries; if anything, price increases were larger in
the unskilled-labour-intensive industries. Rapid technology change seems to
have led to relative price declines in skill-intensive industries rather than the
price decreases in unskilled-labour-intensive industries one would expect in
the face of import competition from developing countries. In most cases,
trade with developing countries have played only a small role, if any, in
raising income inequality in the advanced economies.
Figure 2.7 helps in illustrating that the globalisers (table 2.4) have in fact
been able to increase their wages with openness to trade and not the other
way around. The graph shows that wages move in tandem with openness to
trade but provides no evidence for whether the wages have increased for
skilled or unskilled labour. Therefore, at this point it becomes important to
discuss the effect of liberalisation on income distribution.
2.&..EFFECT OF LIBERALISATION ON INCOME DISTRIBUTION
Even though the growth benefits of trade are progressively getting more
recognised, many analysts are reasonably concerned about the effects of
trade liberalisation on income distribution and the issue of income inequality.
Research undertaken by World Bank indicates (internet 3) that, however,
the growth benefits of increased trade are, on average, widely shared no
evidence has been found of a systematic tendency for inequality to increase
due to increase in international trade (Dollar and Kraay: 2000). Figure 2.8
helps to illustrate this point by plotting changes in a measure of inequality,
the Gini coefficient, which ranges from- 0 to 100, with a higher coefficient
indicating greater inequality on vertical axis and changes in trade volumes
on the horizontal axis (Schiller 2000: 672). This figure shows a picture of
about 100 developed and developing countries with regard to changes in
trade and changes in inequality measures over periods of at least five years
in order to examine the medium-to-Iong-run relationship between trade and
inequality. Figure 2.8 exhibits a striking absence of any such relationship.
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Figure 2.8: Changes in trade and income inequality
Source: Dollar and Kraay; 2003
The conclusion that emerges from this discussion is, that there is little
evidence of a systematic trend for income inequality to either increase or
decrease with increased international trade.
This evidence is also consistent with the experiences of the post-1980
globalisers (figure 2.4). While several of the globalisers have experienced
increases in inequality most notably China, where the Gini coefficient
increased from around 32 in the early 1980s to 40 in the mid-1990s, several
others have seen decreases for example, Malaysia, where the Gini
coefficient fell from 51 to 48 during the same period. In many countries,
large shifts in income distribution can arguably be linked to influences
beyond international trade (Internet 4). For example, in China, domestic
liberalisation, restrictions on internal migration, and agricultural policies have
played a much larger role than increases in international trade (Mathew and
Swagel: 1997).
2.9 EFFECT OF LIBERALISATION AND GLOBALlSATION ON POVERTY
Increases in growth and little systematic change in inequality among the
globalisers have significantly boosted efforts to reduce poverty. For
example, "In Malaysia, the average income of the poorest fifth of the
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population grew at a robust 5.4 percent annually. Even in China, where
inequality did increase sharply and the income growth rate of the poorest
fifth lagged behind average income growth, incomes of the poorest fifth still
grew at 3.8 percent annually" (Dollar and Kraay: 2000). The fraction of the
population of these countries living below the $1 a day poverty line fell
sharply between the 1980s and the 1990s: from 43 percent to 36 percent in
Bangladesh, from 20 percent to 15 percent in China and from 13 percent to
10 percent in Costa Rica,(Martin Rama: 2003).
2.J 0 GLOBALlSATION AND GAP BETWEEN THE RICH AND THE POOR
COUNTRIES
It has already been established that the income gap within countries is likely
to decrease with the increase in trade. What about the gap between the rich
and the poor countries? Is it widening due to globalisation? Are the rich
countries leaving the poor countries behind in this race towards
globalisation? Evidence on the growth performance of the globalisers
relative to the rich countries and the non-globalising developing countries
provides mixed results. On one hand, the rapid growth of the globalisers
relative to the rich countries indicates that the globalisers are narrowing the
per capita income gap. Moreover, countries like China, India, Bangladesh
and Malaysia were one of the poorest countries in the world a few decades
ago but today they are growing at a much faster rate, which has been a
force for narrowing worldwide inequality. At this point it will be useful to look
at figure 2.9 indicating the gap within and between countries. The top panel
of figure 2.9 provides a rough estimate of trends in worldwide inequality over
the past forty years, using the mean log deviation measure of income gap.
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Figure 2.9: The Globalisers and the Worldwide Inequality
Source: Dollar and Kraay: 2000
Figure 2.9 illustrates that worldwide interpersonal inequality has been quite
stable over the past forty years, showing at most a weak downward trend,
which according to Dollar and Kraay (2000) and Martin Rama (2003), is not
of any statistical significance, given the immense difficulties of measurement
inherent in such calculations. More relevant is the effect of the rapid growth
of the post-1980 globalisers on this inequality measure. To show this, the
top panel of figure 2.9 first divides worldwide inequality into inequality
among countries and inequality within countries. Consistent with the findings
of studies undertaken by World Bank, most worldwide interpersonal income
gap can be attributed to the large differences in the purchasing power and
inequalities in income between countries, rather then to inequities in the
distribution of income within countries. Since many of the globalisers were
initially poor, their rapid growth over the past twenty years has contributed to
reducing income inequality between countries.
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Other studies undertaken by Surjit Bhalla (2003), however, indicates that
inequality trends are in line with the "fears of anti-globalisation protesters".
Share of Income and Population across Global Regions
Share of World Population Share of World Income
Region 1950 1960 1980 2000 1950 1960 1980 2000
China and India 41.1 36.5 37.7 37.6 8.4 7.9 6.5 16.8
SUb-saharan Africa 6.6 7.4 8.6 10.9 3.2 3.2 3.0 2.5
Middle East & North 3.8 4.4 5.1 6.2 3.0 3.5 5.1 4.7
Africa
Latin America 6.2 7.2 8.2 8.5 7.7 7.9 9.9 8.4
Eastern Europe 10.2 10.4 8.7 6.8 11.2 11.3 12.6 6.1
Other developing 31 35 39.2 43.7 20.4 21.4 26.0 25.6
countries
Industrialised world 20.2 20.8 17.0 14.0 62.5 61.9 57.2 52.4
Table 2.5: Share of Income and Population across Global Regions
(Source: Surjit Bhalla 2003)
Table 2.5 suggests that there is in fact large contemporary correlation
between globalisation and worsening country and inter country inequality.
According to Kuznets curve (Surjit Bhalla: 2003), "this increase in inequality
was entirely to be expected; that is, things get worse on the inequality front,
with growth, before things get better".
Some studies conclude that globalisation has not widened the gap between
the rich and the poor countries, contrary to our belief it has helped in curbing
that gap and others indicate entirely the opposite (as can be seen in table
2.5 and fig 2.9). However, important fact to take into account is that there
are other factors attributable to widening gap, such as measures to protect
domestic industry by putting in place barriers and internal regulations.
2J.j GLOBALlSATION ANp UNEMpLOyMENT
Even though globalisation prompts both job destruction and job creation, the
timing of these two developments might not be linked (Martin Rama: 2003).
During periods of trade liberalisation, and more generally of economic
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restructuring, job destruction rates can be expected to proceed at a much
faster pace than job creation. Globalisation could therefore be associated
with higher unemployment rates. Furthermore, integration with international
markets could intensify macroeconomic fluctuations. Instability of the terms
of trade and speculative capital flows could lead to booms and busts,
increasing the variability of unemployment rates. Even if the average
unemployment rate remained unchanged over the business cycle, job
turnover possibly will swell, and with it the feeling of economic uncertainty
(Internet19). Before addressing the impact of globalisation on
unemployment, it is important to highlight that the very concept of
unemployment is somewhat ambiguous in many developing countries.
According to the definition given in Schiller (2000), unemployment can be
attributable to seasonal changes (seasonal unemployment), movements in
between jobs (frictional unemployment), mismatch of job seekers and the
requirements of available jobs (structural unemployment) or lack of job
vacancies (cyclical unemployment). These definitions are problematic in
countries where the salaried relationship is not prevalent, and employment
in household enterprises and farms is common.
The countries that are getting poorer are those that are not open to world
trade, notably many nations in Africa. China's opening to world trade has
brought about growth in income from $1460 a head in 1980 to $4120 by
1999 (Internet 3). In 1980, American's earned 12.5 times as much as the
Chinese, per capita (Internet 4). By 1999, they were only earning 7.4 times
as much. The gap between rich and poor is also shrinking with most nations
in Asia and Latin America. People tend to believe that exports create jobs
whereas imports are a source of job destruction and therefore it makes
sense to put in place barriers against imports. This so called 'philosophy' led
to the Great Depression in 1930, because so many countries adopted
import substitution polices that global trade fell with catastrophic
consequences. Most exports also use some imports. To take a simple
example, a country might export packaged sugar, but import the packets.
Lowering import barriers makes export industries even more efficient and
competitive in world markets. Countries that lower trade barriers concentrate
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their national energies in industries they are good at, where they have an
international advantage. Import barriers encourage countries to focus efforts
in industries where they do not have any advantage, which leads to
inefficient use of resources. There is evidence that developing countries that
have adopted import substitution policies have experienced slower growth in
incomes compared to the countries that were more outward oriented.
Figure 2.10 reports the unemployment rates of four successful globalisers,
Poland, Mauritius, Chile and Sri Lanka during the first 20 years of their
reform process. Unsurprisingly, economic policies were not always perfect in
all of them. Chile had a failed experience of exchange rate based
stabilisation, leading to a massive financial crisis. Mauritius was dependent
on its export-processing zone, which is not, theoretically, the most efficient
way to globalise. Poland and Sri Lanka maintained their protection of
bloated and inefficient industries and state-owned enterprises. Still, on
average the economic management of these countries is probably close to
the best that can realistically be expected (Dollar and Kraay: 2000).
Unemployment Rates in Successful G/obalisers
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Figure2.10: Unemployment Rates in Successful Globalisers
(Source Martim Rama 2003)
Chapter Two Literature Review
42 of 88
All four successful globalisers have in common a long period of high rates of
unemployment after the having launched their respective economic reforms.
In the long run, open economies do not appear to have higher
unemployment rates, as suggested by figure 2.10. If anything, their
unemployment rates are lower. However, to the extent that country and
period-specific biases are independent from the degree of openness of the
economy, the pattern described by the figure should be basically correct.
This pattern is one of high dispersion of unemployment rates in more closed
economies, and convergence towards a relatively narrow range in more
open economies (Internet 19).
2J 2 GLOBALlSATION AND ~ATIONAL SOVEREIGNTY
Does globalisation shift economic power away from nation governments
towards organisations like, the World Trade Organisation, European union,
and the United Nations. It is argued that these organisations impose policies
on democratically elected governments, thus undermining the sovereignty of
those economies and limiting their ability to administer its own nation.
According to Ralph Nader (Hill: 2003:28),
Under the new system, many decisions that affect billions
of people are no longer made by local or national
governments but instead, if challenged by any WTO
member nation would be differed to a group of
unselected bureaucrats sitting behind closed doors in
Geneva (which is where the headquarters of the WTO
are located). The bearcats can decide whether or not
people in California can prevent the destruction of the
vast virgin forests or determine if carcinogenic pesticides
can be banned from their foods; or whether European
countries have the right to ban dangerous biotech
hormones in meat...at risk is the vel}' basis of democracy
and accountable decision-making.
However, Governments who choose not to globalise, are at liberty to choose
that road, nevertheless there will be a cost. They may choose the degree of
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their participation in this process. In spite of their integration into the global
economy, governments are still at a liberty to put in place their own
regulations within the wider areas of economic policy such as fiscal,
monetary, budget and exchange rate policies.
The more a country is entwined into the world economy, the more it is
affected by economic and political events around the world. Globalisation
shifts the debate about market mechanisms and competition from the
national to the international level.
National sovereignty per se is not threatened given that there is no coercion
in this process. There may be some pooling or sharing of sovereignty. The
degree of sovereignty-sharing involved is limited when compared to, say,
the real pooling of sovereignty required of the 11 governments whose
currencies now form part of the euro single currency zone. Membership of
NATO involves a considerable curtailment of sovereignty, although in a well-
defined and limited sector (Internet 2).
Governments can help retain local control over certain aspects of economic
decision-making by empowering companies or regional authorities to run
their affairs with more freedom and flexibility by applying the principle of
subsidiarity. This allows decisions to be taken at the level where they will be
most effective. Governments in this manner can limit their action by ensuring
a level playing field for companies and acting against anti-competitive
behaviour. Moreover, when governments are restricted because of
international commitments, companies may be able to act more freely to
develop their business and pursue their international goals.
As the scope for individual action becomes narrower, the need for efficient
governments focusing on crucial tasks will increase. In such a case,
sovereignty may lose in quantity but gain overall through the increased
quality of the actions governments take.
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2,13 CONCLUSION
The study undertaken by World Bank and WTO (Internet 3 and Internet 4)
shows that the 24 developing countries who increased their integration into
the world economy over two decades ending in the late 1990s achieved
higher growth in incomes, longer life expectancy, higher GDP and better
schooling. These countries enjoyed an average 5 percent growth rate in
income per capita in the 1990s compared to 2 percent in the developed
countries (Internet 4). Many of these countries such as China, India,
Hungary and Mexico have adopted domestic policies and institutions that
have enabled people to take advantage of global markets and thus, have
sharply increased the share of trade in their GDP. These countries have
been catching up with the more advanced countries and their annual growth
rates increased from 1 percent in the 1960s to 5 percent in the 1990s
(Internet 3). People in these integrating countries saw their wages rise, and
the number of people in poverty declined.
The shrinking globe due to the integration of the world economy over the
past two decades has been very impressive The experiences of the post-
1980 globalisers show that the process can be very favorable, acting as a
catalyst for rising incomes, falling poverty and enabling some of the poorest
countries in the world to catch up with richer countries. The real losers from
globalisation are those developing countries that have not been able to
seize the opportunities to participate in this process and have hidden
themselves under the blanket of barriers. They live under the delusion that
they are protecting their industry, their people, and their national
sovereignty. However, development, prosperity and growth has been
undermined not by globalisation per se but the way they have treated it, like
a disease from which they have to protect themselves.
It has already been established that, 'Globalisation' is a process, which
involves economic inter-dependence of countries worldwide removing all
barriers for economic integration as if the whole world is a single village.
Together with that concept it is also believed that, in this process, the rich
nations with their superior financial power, control the scenario and the poor
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developing nations are forced to integrate surrendering their economic
independence knowing fully well what they are forced to accept is really
prejudicial to their own interest. In this process the world financial institutions
like the World Bank, IMF and now the WTO advance the interest of the rich
countries alone. The Transnational Corporations (TNCs) and the
Multinational Corporations (MNCs) are practically controlling the world
assets.
As far as developing countries are concerned, there is enough evidence to
suggest that openness is a necessary condition for rapid growth. However,
one can surely find examples of countries opening up without experiencing
growth. So where does the problem lie? Well, because openness by itself is
not sufficient to promote growth, factors such as macroeconomic stability,
policy credibility and other government policies must accompany it.
So where does this leave a nation? Should they liberalise or not? If yes what
policy measures should they take up and where does this leave the
domestic industries and what is their destiny? Can they possibly survive in
this environment, which seems to be dominated by the MNCs and the
TNCs? Lets try and analyse the scenario of 'globalisation' for the
pharmaceutical industry in India, which might help in understanding the
bigger picture that will emerge from it.
"Globalisation is much like fire. Fire itself is neither good nor bad. Used
properly, it can cook food, sterilize equipment, form iron, and heat our
homes. Used carelessly, fire can destroy lives, and towns"(lnternet 19).
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CHAPTER THREE: OVERVEIW OF THE INDIAN
PHARMACEUTICAL INDUSTRY
3.1 INTRODUCTION
In the past, the Indian government established that a developing country like
India possibly could not afford expensive patented drugs. Subsequently
process patents came into existence but product patents failed to find a
place in the Indian pharmaceutical industry. This inadvertently, gave rise to
a robust domestic pharmaceutical industry and took joy out for multinational
pharmaceutical companies. In view of the fact that India's legal system
would not protect product patent infringements, MNC block buster drugs
were never introduced in the market and the 'me too' versions flooded the
market (Gina Singh: 2003). This was evident from the fall in market share of
multinational companies from 70% in the 'era of product patents' (before
1970) to 24% in 1970 (Internet 10).
Now that the winds of liberalisation have caught India and being a signatory
to the World Trade organization (WTO), it will recognise product patents
from 2005 onwards (Gina Singh: 2003). That is why international industry
has once again moved their attention towards India. However, due to the
nature of the industry and progress of the domestic industry, it is believed
that it will take the foreign players at least five years or so after 2005 before
they start showing significant gains.
3.2 GLOBAL INDUSTRY STRUCTURE
At the global level, the pharmaceutical industry is divided into two segments,
the innovative firm and the producer of generic drugs (refer to figure 3.1).
The innovative or patent protected firms rely heavily on patent protection.
These firms believe that patents protection is essential to carry out the
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intensive research required to produce new products. Since, patents provide
period of exclusivity, it leads to higher drug prices. As a result of this
phenomenon, they are predominant in the developed countries.
Alternatively, generic drugs are not subject to patent protection. They are
only subject to government regulation. Generic firms emerge at the
expiration of the patents. Since, technology is in public domain and anyone
is free to capitalise on it and manufacture the product, usually generic drugs
are available in the market at a lower price than the original patented
version. Due to their nature, they are predominant in the developing
countries such as India (figure 3.1).
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Figure 3.1: Structure of the pharmaceutical industry at a global level
(Source: Robert Tancer and Srinivas: 2000)
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3,3 OVERVIEW OF THE INDIAN PHARMACEUTICAL INDUSTRY
The Indian pharmaceutical industry is a success story
providing employment for millions and ensuring that
essential drugs at affordable prices are available to the
vast population of this sub-continent. However, the new
'trade'rules of the World Trade Organisation now pose a
serious threat to the industry and to the millions who are
dependent on it for their health and livelihood.
(Richard Gerster: Internet 5)
India has an extremely efficient pharmaceutical industry, which has been
experiencing robust growth attributable to the virtual absence of patent
protection of medical drugs (Gina Singh: 2003). This allows the firms to
produce relatively cheaper drugs, for example, AIDS drugs are sold
relatively cheaper than the original products from overseas. It is now
believed and indicated by reports of the Chamber of Indian Industries
(Internet 10), that the new policies of the World Trade Organisation (WTO)
benefit the pharmaceutical multinationals from countries such as the USA,
Great Britain and Switzerland, and threaten India's achievements (Internet
6).
Despite the winds of liberalisation and turbulence due to the new patent
regime, Indian pharmaceutical industry has advanced perceptibly and is
getting ready to withstand global competition. "The industry has expanded at
annual rates ranging between 15% and 20% against global growth rates of
6%"(lnternet 5).
India ranks 1i h among the drug producing countries in value terms, and 5th
in volume terms, with an 8% share of the global pharmaceutical production
market and with a global market share of 1.2% (Internet 5). Today it is in the
front rank of India's science-based industries with wide ranging capabilities
in the complex field of drug manufacture and technology. A highly organised
sector, the Indian Pharmaceutical Industry is estimated to be worth $ 4.5
billion. It ranks very high compared to the other third world countries, in
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terms of technology, quality and range of medicines manufactured. From
simple headache pills to sophisticated antibiotics and complex cardiac
compounds, almost every type of medicine is now made indigenously
(Internet 9). The number of pharmaceutical companies in India multiplied
dramatically from 3000 in 1977 to 24,000 in 1997 (Robert Tancer & Srinivas
Josyula: 2000).
India is self-sufficient in all most all its formulation and bulk drug
requirements, exporting around 33% of its annual production. India imposes
strict control on drug prices in order to ensure availability of medicines at
relatively low prices through the rigid provisions of the Drug Price Control
Order (DPCO), which trims down the profitability of the industry. Currently,
74 drugs are under DPCO and 260 formulations that use these bulk
ingredients (Internet 8).
"India's lack of product patent laws further hindered foreign direct
investment and deterred the MNCs from investing in India" (Robert Tancer &
Srinivas Josyula: 2000). Introduced in 1970, the Indian Patent Act
recognised process, but not product patents making the market highly
competitive with extremely low drug prices, at the same time discouraging
Indian companies from developing new drugs. Post 2005, product patents
will come into force (Gina Singh: 2003).
Research and development expenditure by Indian companies are small
relative to the global scenario. Nevertheless, it has been growing at a CAGR
(compounded annual growth rate) of 14% (Internet 6).
The Indian Pharmaceutical sector is highly fragmented with more than
20,000 registered units. It has expanded significantly in the last 20 years.
The leading 250 pharmaceutical companies control 70% of the market with
market leader holding nearly 7% of the market share (Internet 9). It is an
extremely fragmented sector with severe price competition and government
regulation of price.
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The pharmaceutical industry in India meets around 70% of the country's
demand for bulk drugs, drug intermediates, pharmaceutical formulations,
chemicals, tablets, capsules, orals and injectibles. There are about 250
large units and about 8000 small-scale units, which form the essence of the
Indian Pharmaceutical industry (including 5 Central Public Sector Units).
These units produce the complete range of pharmaceutical formulations,
i.e., medicines ready for consumption by patients and about 350 bulk drugs,
i.e., chemicals having therapeutic value and used for production of the
pharmaceutical formulations.
Indian Pharmaceutical Market: Market Share Based on Country of Origin







Figure 3.2: Indian Pharmaceutical Market: Market Share Based on Country of Origin
(Source: Robert Tancer & Shrinivas Josyula)
Following the de-licensing of the pharmaceutical industry, licensing for most
of the drugs and pharmaceutical products has been done away with.
Companies are at a liberty to produce any drug, approved by the Drug
Control Authority. Technologically strong and totally self-sufficient, the
pharmaceutical industry in India has maintained a low production cost, low
R&D costs, innovative scientific manpower, strength of national laboratories
and an increasing balance of trade. The Pharmaceutical Industry, which
consists of affluent scientific talents and research capabilities, sustained by





The industry is classified into the organised and unorganised sectors. There
are around 250 manufacturing units in the organised sector, which account
for 70% of total sales (Internet 9). The organised sector can be further
classified, on the basis of management control, MNCs and Indian domestic
companies. Indian firms producing 63% of the industry sales, multinational








Figure 3.3: Industry Sales
(Source: Internet 9)
Foreign firms, especially U.S, U.K and German firms are more active in
formulations or branded products in contrast to Indian firms, which
concentrate more in bulk and generic drugs. Indian manufacturers market
under their own brands and manufacture drugs in virtually every therapeutic
category of the market. For example, in the anti-ulcerant therapeutic
category Zinetac the Indian brand name for Zantac (Ranitidine, the
molecular form) was manufactured by Glaxo (Internet 5). There were nine
subsequent "me too' drugs introduced by the Indian firms within a few years.
As a result, the prices dropped by about 50% (table 3.1).
Chapter Three
52 of 88




US Price per Indian Price per
Name Tablet ($) Tablet ($)
PriloseclAstra
Omeprazoler 20 mg $3.76 $0.09
Merk
Prozac/Eli Lilly Fluoxetine 10mg $2.28 $0.63
Zocor/Merk Simvastatin 10 mg $2.07 $0.21
ZantaclGlaxo
Ranitidine 150 ml $1.72 $0.02
Wellcome
Table 3.1 Price Comparisons of certain Drugs in US & India
(Source: Robert Tancer & Srinivas Josyula: 2000)
3.3.1.1 PHARMACEUTICAL SALES AND DISTRIBUTION STRUCTURE
Figure 3.4 depicts the Indian pharmaceutical sales and distribution structure.
Overall, pharmaceutical sales (fig 3.4) and marketing systems are amongst
the most complex and challenged across industries. Among the most
fragmented, expensive sales and marketing systems will pose a huge
management challenge
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Figure 3.4: Pharmaceutical Sales and Distribution Structure
(Source: Confederation of Indian Industry: 2000)
3.3.1.2 MARKET SHARE
The share of MNCs, who once dominated the Indian pharmaceuticals
market, has dropped from 75% in 1971 to 35% in 2000. Among the MNCs,
American, German and UK firms have most of the market share (figure 3.2).
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Table 3.2 depicts the market share of the tops firms in India, both domestic
and MNCs. The market share of the MNCs might increase since foreign
investments are permitted up to 74% through the automatic approval route.
Indian Pharmaceutical Market: Market Share of Top Companies
Ranking Company Value in (OO's Indian Market Share
Rupees) (%)
Total Market 113018645 100
1 Glaxo Wellcome 7477107 6.62
2 Cipla 4783702 4.21
3 Ranbaxy 3985928 3.51
4 Hoechst-Roussel 3576615 3.17
5 Torrent Pharma. 2648258 2.34
6 Wockhardt-Merind 2642186 2.34
7
Alembic 2640003 2.34
8 Lupin Labs 2428777 2.33
9 Knoll Pharmaceuticals 2501779 2.21
10. Pfizer 2495387 2.21
11. Nicholas Piramal 2456205 2.17.
12 Zydus Cadila 2294898 2.03.
13 Novartis India Limited 2194014 1.94.
14 Cadila Pharma 2138017 1.89.
15 Wyeth Lederle Limited 2026379 1.79.
16 Alkem Laboratories 1980530 1.75
17 Smith Kline Beecham 1917397 1.70.
18 Aristo Pharma 1885731 1.67
19 Sun pharma 1821173 1.61.
20 Parke Davis 1717831 1.52
21 E Merck 1654896 1.46
22 Dr Reddy's Laboratory 1593352 1.41
23 Unichem Labs 1551258 1.37
24 Himalaya Drugs 1402590 1.24
25 German Remedies 1354380 1.20
Table 3.2: Indian Pharmaceutical Market: Market Share of Top Companies
Source: Robert Tancer and Srinivas
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3.3.1.3 PRODUCTS OF THE INDUSTRY
The products of pharmaceutical industry can be broadly classified into bulk
drugs and formulations. The Indian market has more than 10,000 drugs and
around 2,400 licensed manufacturers. Bulk drugs constitute nearly 19.1 % of
the market and formulations account for the remaining 80.9% (Internet 5)
The share of bulk drugs and formulations has remained relatively stable
over the years.
Formulations prepared using a bulk drug under patent are called branded
formulations. Formulations, which do not contain any patented bulk drug,
are known as generics. In developed countries, where the patent structure is
regulated, generics can be manufactured only after the expiry of a patent.
However, in India, the patent system is yet to be implemented (Business
world 2003).
The total size of the domestic formulations market is Rs 159.6 billion
(approximately $ 3.192 billion). The market is characterized by
fragmentation with respect to therapeutic segments (figure 3.5). The
antibiotics segment is the largest, accounting for around a 17% share of the
domestic retail market. Vitamins and mineral supplements come next, with a
domestic retail share of 7%. Currently, the top 18 therapeutic segments
account for around 88% of the domestic retail (figure 3.5).











Figure 3.5: Main Therapeutic Segments (in percentage)
(Source: Internet 9)
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With increased life expectancy and industrialisation, the industry is
witnessing an increasing tilt towards high margins, lifestyle therapeutic
segments. The large and traditional antibacterial plus systemic antibiotics
segment of the market has grown by a mare 5.9% in 1999, compared to
15%,27% and 20 % in 1996, 1997 and 1998 respectively (Internet 9).
3.3.2 PHARMACEUTICAL INDUSTRY PRIOR TO THE ADVENT OF INDIAN
PATENT ACT
At the time of independence, the total drug production in India was around
Rs 100 Million. During that time the MNCs with the help of the colonial
Patent and Designs Act, 1911 exploited India's drug market. Engaging
mainly in the import of drugs from their country of origin. Between 1947-57,
99% of the 1704 drugs and pharmaceutical patents in India were held by
foreign MNCs. During that time the MNCs who were controlling 80% of the
market did not come forward with financial investment and technological
help to establish drug production centres in India. Drug prices in India were
amongst the highest in the world. In 1954, the first public sector drug
company Hindustan Antibiotic Ltd. (HAL) was established with the help of
WHO and UNICEF (Internet 9). The Indian Drugs and Pharmaceutical
Limited (IDPL) was established in 1961 with help from the Soviet Union
(Internet 8). The establishment of these two public sector units and the
coming into force of the Drug Policy of 1978 had been mainly responsible
for the availability of drugs and medicines at relatively lower prices in India.
3.3.3 INDIAN PATENT ACT 1970
The Patent Bill was first introduced in Parliament in 1967, which came into
force in 1972. The act does not allow product patents on medicines,
agricultural products and atomic energy. This is considered to be the most
suitable patent act for the developing world whereby process patents are
allowed for 5-7 years. Owing to the patents act, today India is self-sufficient
in the production of basic drugs covering various groups of drugs. Indian
companies are now among the world leaders in the production of bulk drugs
from basic stages. At present, drugs in India are very competitively priced
compared to other countries. According to Confederation of Indian Industry
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(Confederation of Indian Industry: 2000), India is identified to produce its
own drug needs with its own technology and manpower. After 1970, Indian
businessmen established many new pharmaceutical firms. At present,
around 23 thousand small, big, and medium firms are producing drugs in
India.
Attempts to alter the Indian Patent Act 1970 are a part of this globalisation
programme. It is believed that the imposition of an unequal trade treaty like
the World Trade Organisation (WTO) is a step towards globalisation in
favour of the MNCs of rich and developed nations. With its help, the market
of the developing nations is forced open for the developed countries. Most
of the developing countries were forced to sign the WTO agreement without
realising its implication: as a result, the developed countries are the gainers.
Already, at the dictates of the IMF, World Bank and WTO, the Government
of India is slackening all barriers in order to invite the MNCs in all industries
including the pharmaceutical industry. Foreign Exchange Regulations Act
(FERA) and Monopolies and Restrictive Trade Policies Act (MRTP) have
been amended. Customs duties and corporate taxes have been lowered
(Internet7). Relief, concessions and facilities have been extended to the
MNCs as to Indian companies. All these, already, had an adverse impact on
the indigenous Pharma industry. As per the requirement of WTO guidelines
for the product patent regime, the availability of new drugs in India may be
delayed depending on the desire of the patent holders. As per the
guidelines, a product patent is granted 20 years and a process patent
another 20 years (Internet 7). At present, newer drugs are made available in
India within a 4-6 years period. Prices of drugs will go up by 5 to 10 times as
it is evident from the prices of drugs in India and other countries like
Pakistan, U.K. and U.S.A. where product patents are in force. In India,
Ranitidine manufactured by Glaxo is put on the market at Rs. 7.20. In
Pakistan and United States the same products by the same company is
priced at Rs 65 and Rs 545 respectively (Internet 10). Similarly, the anti-viral
drug Aciclovir costs Rs. 33.75 in India while the same drug is sold in
Pakistan at Rs. 363 (Internet 5). There are many such examples. The drug
prices in the U.S.A., U.K. and other developed countries have gone up so
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high that the health care expenditure in those countries is predominantly
funded by insurance companies at a very high premium. In those countries
people cannot think of treatment without insurance coverage. Product patent
regime will definitely hamper India's drugs exports, as countries will be
forced to purchase from patent holders only (Gina Singh: 2003).
3.3.4 DILUTION OF DRUG POLICY AND DRUG PRICE INCREASE
Unlike consumer goods, drugs are not purchased by the preference of a
person, but on a doctors' prescription. Prices of drugs are increasing by
leaps and bounds along with the prices of other commodities in recent
times. The drug manufacturers are flouting the Drug Price Control Order
(DPCO). The DPCO was first introduced in 1970. In 1970 most of the drugs
were under price control. In 1987 this was diluted and the number of drugs
which were restricted declined to 347, in 1987 it was brought down to 163
drugs and in 1994 only 73 drugs were under DPCO (Internet 9). The
industry wants the control to be abolished altogether. They have already
demanded decontrol of 17 bulk drugs and further recommended full
decontrol within 3 years time (Confederation of Indian Industry: 2000). Many
developed countries in Europe and United States control drug prices
directly. In the U.K., the government determines the profit level of drugs
supplied by individual companies. A company has to reimburse excess
profits to the Department of Health.
A recent study by the Confederation of Indian Industries (2001) shows that
the prices of many life-saving bulk drugs have gone up precipitously. Drug
policies in India are not decided by the need, the pattern of diseases or the
purchasing capacity of the individuals, but by the profit motive of the industry
and the Central Government is playing the role of a silent onlooker.
Given below (figure 3.6) are the prices of twelve essential drugs and the
percentage increase in the prices after the liberal decontrol of DPCO.
Chapter Three Overview of the Indian Pharmaceutical Indul"trv
58 of 88
Percentage Increase in the Drug Prices over the
Period 1995-2000
Percentage Increase in the Prices
Figure 3.6: Percentage Increase in the Drug Prices over the Period 1995-2000
(Source: Internet 5)
Figure 3.6 is only indicative, hundreds of such examples can be given.
Further, under the WTO agreement and the imposition of a products patent
regime, the prices of all new drugs (patented) will go up without any control
of domestic law. The DPCO will become further irrelevant and Indian
people's accessibility to newer drugs will be restricted only to the rich of the
country. Table 3.3 presents the high prices of some of the new drugs
introduced in 1997 in the Indian market.
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Prices of some of the New Drugs Introduced in 1999 in the Indian Market
Drug Company Strength Pack Price in Rs
Sporanox Ethnor 100 mg 4 tablets 173.00
Lumicil Novertis 250 mg 14 capsules 1247.00
Spariex Sun Pharma 200 mg 6 tablets 154.00
Rispid Panacea 50 ml 1 mg/ml 141.00
capsule
Livial Infar 2G 28 tablets 1225.00
Pipracil Cyanamid 2G Vial 215.78
Amate Mesco 50mg 12 tablets 180.00
Pharma
Adnoject Inca 3 mg 2 ml. vial 210.00
Roxisara Sarabhai 300 mg 6 tablets 165.00
Celex Glaxo 250 mg 4 tablets 140.00
Table 3.3: Prices of some of the new drugs introduced in 1999 in the Indian market
(Source: Internet 5, 11,12,13and14)
3.3.5 TRADE
Domestic and international trade are both important indicators in providing a
picture of the competitiveness of a particular industry. They not only provide
a picture of the competitiveness but also tell a story with regards to the tariff
and non-tariff barriers. The countries openness to trade indicates that there
are fewer barriers in place. Similarly, with regards to the Indian
pharmaceutical industry, it can be seen that over the past decade both
exports and imports have gone up both in terms of world trade and domestic
trade (refer to table 3.4 and 3.5 and figure 3.7).
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World Trade in Pharmaceuticals 2000
World Trade In pharmaceuticals 2000
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Table 3.4: World Trade in Pharmaceuticals 2000
(Source: Internet 10 and 6)
3.3.5.1 DOMESTIC TRADE
More than 85% of the formulations produced within the country are sold in
the domestic market. As far as formulations are concerned, India is largely
self-sufficient. However, some life saving, new generation under-patent
formulations continue to be imported, predominantly by MNCs, which are
then marketed in India. Overall, the size of the domestic formulations market
is around Rs 160 billion (approximately $ 3.2 billion) and continues to
increase at a growth rate of 10% per year (Internet 10).
3.3.5.2 EXPORTS AND IMPORTS
More than 60% of India's bulk drug production is exported. The remaining is
sold locally to other formulators. India's pharmaceutical exports account for
approximately Rs 87bn, of which formulations contribute nearly 55% and the
rest of the 45%, comes from bulk drugs. In financial year 2000, exports grew
by 21 % (Internet 10).
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Imports accounted for about Rs 20.3bn in the years 2000-2001. Imports
have registered a CAGR of only 2% in the past 5 years. Import of bulk drugs
have slowed down in the recent years (Internet 5).
During the years, 1997-98 exports accounted for Rs 49,780 million. From as
little as Rs 460 million worth of Pharmaceuticals, Drugs and Fine Chemicals





Capital Investment 1400 2,5000
Production:
Formulations 1500 15,9600
Bulk Drugs 180 3,7770
Import 820 3,4410
Export 305 6,6310
R&D Expenditure 30 3200
Table 3.5: Growth Indicators
(Source: Internet 5 and 10)
Indian pharmaceutical exports have been on the rise continuously over the
past few years (figure 3.7 and table 3.5). The low prices of drugs in India
have enabled domestic producers to be cost effective and competitive,
which has resulted in growth of export at a CAGR of 26.7% in the period
between 1990-1991 and 1999-2000 (Internet 10).
Due to the fact that India is endowed with natural resources best suited for
manufacturing drugs other related medication, MNCs have identified India
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as a source base for their raw material requirements. The current export
targets are China, USA, UK, Brazil, South East Asia and other developed
countries.
Drugs and Pharmaceuticals Export
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~4 THE CONSOLIDATION WAVE
With the advent of globalisation the industries are hit by consolidation wave.
As already discussed in chapter two, with the globalisation of the world
economy, companies are growing by joint ventures, mergers and
acquisitions and other forms of strategic alliances to stay competitive, cut
costs, share resources both human and capital, share technology, expertise
and network. Similarly, the pharmaceuticals industry, both global and
domestic, has been hit by the consolidation wave (table 3.6).
3.4.1 STRATEGIC ALLIANCES
International and national level mergers; acquisitions, takeovers and other
forms of strategic alliances have now become a common phenomenon in
the pharmaceutical industry. American Home Product merged with
Cyanamid, SKB with Sterling, Rhone Poulenc took over Fashions, BSF with
Boots, Glaxo with Burroughs Welcome, Ciba Geigy with Sandoz, Warner
Hindustan with Parke Davis, Hoechst with Rhone Poulenc etc. are some of
the examples of big mergers and acquisitions (Internet 10 and 11). By this
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form of strategic alliance, these companies became even larger compared
to their competitors by further adding to their financial resources (See Table
3.6 for the top pharmaceuticals of the world).
Some top Pharma Company mergers in the world
Company Merger Year of Value of
merger merged company
Dow Chemicals Marion Labs 1986 $ 6.21 bn.
Bristol Myers Squibb Corp 1989 12.09 bn.




American Cynamide 1994 9.7 bn.
Products
Hoffman La Roche Syntex Lab. 1994 5.3 bn.
Eli Lyly PCS Health System 1994 4 bn.
Sandoz Gerber 1994 3.7 bn.
Smith Kline Beecham Sterling 1994 2.9 bn.
Glaxo Burroughs Wellcome 1995 14.2 bn.
Hoechst MMD Roussel 1995 7.2 bn.
Pharmacia Upjohn 1995 7 bn.
Rhone-Poulenc
Fison 1995 2.7 bn.
Rorers
BASF Boots 1995 1.3 bn.
Ciba Geigy Sandoz 1996 30.1 bn.
Hoffman la Roche Comage Ltd. 1997 11 bn.
Hoechst A.G. Rhone Poulenc 1998
Astra Zeneca 1998 67 bn.
Table 3.6: Some top Pharma Company Mergers in the World
(Source: Internet 10 and 11)
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3.4.2 BRAND ACQUISITION
There have been a large number of brand acquisitions in the Indian
pharmaceutical sector. Ranbaxy, which focused largely on anti-infectives
acquired brands from Gulfic, Crosslands, and Vorin Labs, which provided
them presence in dermatology, cardiology, CNS to name a few. In 1999, Dr
Reddy's acquired five brands from Dolphin Laboratories and the same year
Nicholas Piramal Acquired two brands, Omnatax and Haemacell from
Hoechst (Internet 9, 10, 11). This trend is likely to continue with larger
companies continuing to look for acquisitions from smaller players.
llBESEARCH AND DEVELOPMENT
Research and development is the backbone of the pharmaceutical industry.
In India, despite the large base of scientific manpower, investment in
research and development as a whole has been low, at around 2% of the
turnover, whereas worldwide, 15-20 percent of the total turnover is invested
in research and development (Internet 10).
In consequence of the Indian patent law introduced in 1970, which
recognized only process patents, India's R&D forte has been in synthetic
organic chemistry and process development. A few new drugs, using
conventional screening techniques, have emerged from Indian R&D, but
none have been as successful as they would have liked to be without
product patents, domestic firms have grown their indigenous market through
creation of different processes. The low investment in R&D is attributed to
small size of the companies and low levels of profitability.









As a percentage of sales 2%
Table 3.7: Trends in R&D expenditure (in Rs '00 million)
(Source; Internet 5)
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The scenario is however, changing. Pharmaceutical companies such as
Ranbaxy, Cipla, Cadila and Wockhardt now spend between 4%-7% (table
3.8) of their turnover on research and development.







Dr Reddy's Laboratories Limited
Unichemindia
Wockhardt Limited










Table 3.8: Percentage of turnover invested in R&D during 1998-2000
(Source: Internet 11-18)
In the last one decade, the focus of R&D has shifted from process research
to discovering new products, hence driving companies towards original
research. A few domestic companies for instance, Or Reddy's Laboratories
(Internet 15) and Ranbaxy have already ventured into basic research
(Internet 14).
Drug innovation is a drawn-out and expensive procedure. It takes about 10-
12 years for a molecule to reach the market, from the time it is discovered.
The whole process can cost up to $200-500million. The success rate of drug
innovation is around 0.1 % and few drugs even recover average
development costs. In India however, the cost of discovering a drug could
be as low as Rs 1.4-2 billion (Internet 10). This provides great opportunity
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and competitive strength for drug discovery within the country. India
currently contributes to just 0.1 % of the global new drug delivery market,
currently worth $24 billion. With the market expected to increase to $74
billion, post-2005, the drug delivery market will offer immense scope for
Indian pharma players (Confederation of Indian Industry: 2002).
Lack of knowledge of clinical trials procedures and high cost of overseas
clinical trials result in Indian companies tying up with MNCs for carrying out
clinical trials, pre and post clinical studies, under licensing
arrangement/milestone payment. In this arrangement cost of clinical trials in
developed countries is borne by the licensee. Dr Reddy's is the first Indian
company to license its two anti-diabetic molecule to an MNC, Novo Nordisk
for clinical trials (Internet 15).
Percentage of Drug Production and World Population in Some Countries









Table 3.9: Percentage of Drug Production and World Population in Some Countries
(Source: Internet 5 and Internet 10)
3.6 CONCLUSION
The focus of this chapter was to provide an overview of the Indian
pharmaceutical industry both in terms of national and global scenario. Brief
illustration of global industry and where Indian industry fits in was presented.
Current situation and situation dating back to the 1970s was discussed with
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regards to domestic trade, exports, imports and strategic alliances. The next
chapter will focus on the analysis of some of the aspects discussed in this
chapter, against the literature discussed in chapter 2.
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CHAPTER FOUR: CASE ANALYSIS OF THE INDIAN
PHARMACEUTICAL INDUSTRY
UjNTROpUCTION
The structural adjustment program introduced by the government of India at
the behest of the IMF, World Bank and WTO created a serious impact on
India's drug industry, health care system, the workers engaged in the industry
and ultimately on the people of the country. These reform policies are mainly-
the reduced role of the Government, cut in subsidy in the social sector,
increase in administered prices, liberalisation of trade, providing incentives for
foreign investment, privatisation of the public sector, equating foreign
companies with Indian companies, de-regulating the labour market and so on.
This is aimed at the withdrawal of the state intervention from the social and
welfare sectors like health, education and public distribution.
~MPACT OF TRADE LIBERALISATION
With the advent of WTO and Uruguay Round of talks, the Indian
pharmaceutical companies will have the right to patent products as well as
processes. This in turn would give access to international technology, foreign
investment, research and development and global marketing. However, most
alarming results arising from 'trade liberalisation' or WTO agreement would be
hike in drug prices and fierce competition from the multinational companies.
4.2.1 IMPACT OF LIBERALISATION ON DRUG COMPANIES
According to Indian Reserve Bank, liberalisation has made companies like
Ranbaxy, Cipla and Zydus Cadila, more competitive and efficient (Internet 5).
De-licensing means that the companies can now produce as much as they
want and export freely. Thus removing major obstacle to growth. The
indigenous companies can now invest overseas more freely and remit funds
to foreign partners, enabling Indian business to grow internationally.
-
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However, bureaucratic obstacles and mindsets remain. Indian corporate
houses still lack the financial resources to compete with global giants.
Rabbaxy for instance cannot compete with Glaxo. This has led to major
mergers, acquisitions and other forms of strategic alliances with the foreign
multinationals that have the much-needed financial resources. The
government can help by providing research and development support.
4.2.1. 1 IMPACT ON COMPETITION
An essential concern that emerges from the economic restructuring and the
liberalisation of the pharmaceutical sector is increase in competition. The
Indian Pharmaceutical firms faced a similar situation prior to 1970, that is,
before the advent of Indian Patent Act 1970. However, the pharmaceutical
sector was still in its infantile stages and, therefore was hit badly by foreign
competition. As a result, most of the companies closed down or went into
liquidation.
Even though, the Indian patent act of 1970 (which recognized process but
not patents) made the market highly competitive by encouraging low drug
prices and protecting the Indian industries from competition. Nevertheless, it
discouraged Indian companies from developing new drugs.
However, at present, the scenario is different mainly due to the nature of
Indian pharmaceutical sector, which is more developed in terms of expertise
and infrastructure. Furthermore, has the ability to develop new drugs. It
seems that competition will make the domestic firms more efficient,
innovative, facilitate more efficient use of resources and improve the overall
standard and quality. Eventually, this would benefit consumers in the form of
better and more efficient health care system that will emerge from the
competition.
4.2. 1.2 STRATEGIC ALLIANCES
It was established in chapter three that the industry is witnessing a
consolidation phase, with the companies increasingly looking to step up
growth by mergers, joint ventures, acquiring companies or brands. As India
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is slowly moving towards the WTO norms, the consolidation pharmaceutical
companies will increasingly become similar to that of the global trend.
It has already been established in chapter two that, 'pressure on prices has
made Multinational Companies (MNCs) to resort to mergers and
acquisitions and other forms of strategic alliances in order to contain cost
and enhance research and development'. Joint ventures and other forms of
strategic alliances have occurred between Indian and foreign
pharmaceutical firms to gain access to financial resources for co-marketing,
gain access to international technology, brand building or sharing
technology and to enter international markets.
A Conceptual Framework for Strategic Alliances with regards to the
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Process and Production Equipment
Market and distribution network
Brands
o Expanding market access, both nationally and internationally
o Intemational market penetration for the domestic
pharmaceutical firms
o Access to capital resources and foreign investment for the
domestic pharma companies
o Building competitive advantage
o Access to new technologies
o Co-marketing
o Brand building through brand acquisition
o Increased brand power
o Overall operational synergy
o Greater cooperation through increased awareness of each
other
Figure 4.1: A conceptual framework for strategic Alliances
(Source: Sindhwani: 2003)
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For example Zydus Cadila, with the acquisition of German Remedies
Limited and Banyan Chemicals, Zydus Cadila's manufacturing premises
now comprise 9 plants including its existing plants at Moraiya in Ahmedabad
and Ankleshwar. The Zydus Byk Healthcare plant at Navi Mumbai also
commenced commercial production in 2001-02, taking the group's tally to
nine fully operational, state-of-the-art manufacturing plants spread over
three states of Gujarat, Maharashtra and Goa (Internet 13). This further
shows, how the pharmaceutical companies are forming strategic alliances in
order to capitalise on each other strengths and hence leading to growth of
the company. Figure 4.1 helps to illustrate how companies pool their
resources, capital, human and capitalise on each other's strengths, helping
each other penetrate markets, which are otherwise inaccessible. It is clear
from the example of Zydus Cadila (refer to fig 4.1 & 4.2), how with the help
of acquisitions it is now operation 9 state of the art plants and marketing its
products efficiently.
Strategic Alliances: Zydus Cadila
Companies


































Sun Pharma Desloratadine Neoloridine
Table 4.2: Co-Marketing: Zydus Cadila
(Source: Internet 13)
In future, with the help of international financial companies, the MNCs will
capture and take control of Indian companies to control the Indian market.
To match the situation created by international mergers and takeovers,
Indian companies are adopting the same path. For example, Wockhardt
took over Merind and Tata Pharma, Ranbaxy took over Croslands, Nicholas
Piramal took over Roche, Boehringer, Sumitra Pharma. The inevitable
results are job loss of workers. Because of overlapping of jobs large
numbers of workers are declared surplus and thus retrenched. After merger
Glaxo-Welcome and Ciba-Sandoz announced a reduction of 15 thousand
and 10 thousand of their work force respectively worldwide. Upjohn and
Pharmacia decided to close 24 of their 57 plants in different countries after
their merger (Internet 6).
Some countries are adopting the 'buy and grow' method (Internet 5). Which
means taking over some popular brands and increasing business. SKB took
over Crocin from Duphar, Ranbaxy took over 7 leading brands from Gufic,
Dr. Reddy's Lab purchased 6 products of Dolphin and two each from Pfimex
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and SOL Pharma. Sun pharma purchased all leading brands of NATCO,
after selling the popular brands the companies are becoming unprofitable
and closing their shutters throwing the workers on the street.
The government's policy to grant permission to the MNCs to enter the Indian
market with 100% equity as a consequence of the WTO and Uruguay round
of talks, have threatened the existing companies and their employees.
Through the process of mergers, acquisitions and takeovers MNCs will
gradually perpetuate their grip on the Indian industry by the creation of a
limited number of mega companies having monopoly control and domination
worldwide. In the absence of competition, people will have to pay any price
as it happens in the sellers market.
Over the last 6 years, the market share of the top 20 players has increased
to 50% from 35% in the Indian industry. To leverage costs and increase
market presence both in India and globally, the coming year will see the
takeover of medium and small players by the large players. Domestic
players and multinationals would enter into alliances of all conceivable kinds
like technical, marketing and contract research and manufacturing, licensing
arrangements.
4.2.2 ECONOMIC DEVELOPMENT: R&D, INTERNATIONAL TECHNOLOGY
AND FOREIGN INVESTMENT
In a recent World Bank report, 81 % of US research-based pharmaceutical
companies complained, 'intellectual property protection is too weak in India
to permit licensing of their newest or most effective technology and zero
percent would invest in research and development" (Internet 3). Therefore,
strengthened patent protection is expected to encourage foreign direct
investment in India. The study stresses that an environment hospitable to
foreign innovative technology sets in motion a range of other dynamics such
as licensing, co-marketing and joint ventures, generating multiple effects
that befits local drug manufacturers which could prove very helpful for
further development and growth of pharmaceutical industry. For example, in
Malaysia, the level of foreign direct investment increased significantly as a
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consequence of TRIPS (Trade Related aspects of Intellectual Property
Rights) agreement. Currently the foreign direct investment in Malaysia is 11
times that of India (Internet 3).
Deregulation, patent protection and inflow of foreign direct investment, could
improve the quality of medical care in India, as the country progresses from
a copying or a 'me too' culture, towards one that induces local innovations.
However, the extent to which liberalisation and intellectual property regime
will have a direct impact in stimulating research and development remains to
be seen. Nevertheless, it is estimated to go up to 7-10% of the tu rnover or
sales (Internet 5).
It is believed that profits generated from patent protection and international
trade will be invested in research and development by indigenous firms,
thereby stimulating innovation and competitiveness of the domestic industry.
In addition, greater inflow of foreign capital is essential for overall economic
development of a country.
4.2.3 REDUCTION OF WORK FORCE
Many drugs manufactured in India have become unfeasible in the Indian
market compared to the foreign drugs as a consequence of reduction of the
trade barriers on foreign imports such as customs duties. As a result,
factories are either being closed down altogether or downsizing leading to
the retrenchment or throwing the workers out of employment.
Messrs. Boehringer Mannheim, and Parks Davis who were the lone
producers of Chloramphenicol in India stopped their production, as its prices
in the international market were cheaper than the cost of production in India.
M/s. Sarabhai Chemicals closed their Vitamin 'C' plant for a similar reason.
Like Chloramphenicol and vitamin 'C' many other drugs like, paracetamol,
metronidazole, ampicillin, amoxycillin and so on manufactured overseas are
available at a cheaper price in India due to the lowering of the customs
duties.
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In their attempt to shift the production to the third party manufacturing,
Hindustan Ciba Geigy, Roche, Abbot, Boehringer Mannheim, Boots, Park
Davis, Unichem etc. have closed their factories and offered a voluntary
retiring scheme (VRS) to workers. Apart from these closures, Pfizer, Rhone
Poulenc, Hoechst, Glaxo etc. have reduced their work force. These
companies are manufacturing their products with the help of loan licenses.
Some of the companies have opened new smaller factories in new places
and appointed workers with lower wages. More casual workers are being
appointed. According to one source, "In the last two years in the Mumbai.
Thane region of Maharashtra around 30,000 workers have lost their jobs in
the pharmaceutical industry" (Internet 5).
Apart from the factory workers, the distribution workers are gradually being
replaced by Cost & Freight agency system. In this system, the original
company does not have any responsibility for the workers. They are
employed by agencies with lower wages. In the last decade around 15
thousand distribution workers have lost their jobs in the pharmaceutical
industry (Internet 7). Moreover, through the agency system, the government
is deprived of sales tax as well.
In marketing also, the field workers or the sales promotion employees are
facing tremendous attacks in the name of franchise, co-marketing,
appointment of communicators etc. many permanent sales promotion
employees are losing their jobs. Many others are appointed in the name of
so-called executives to remove them from the fold of the union. More casual
and contractual workers are being recruited.
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Reduction of Worldorce
Company Year Reduction of Workforce
Glaxo 1995 1564
Hoechst 1996 1049
Knoll Pharma 1995 600(all workers)
Smith Kline Beecham 1995 208
E. Merck 1995 194
Rhone Poulenc 1996 700
Hindusthan Ciba Geigy 1993 907
Duphar Interfran 1996 154
Bayer 1996 590
Abbott 1996 All workers
Roche 1996 320 (All workers)
Boehringer Mannheim 1997 335 (All workers)
Park Davis 1997 650 (All workers)
pfizer 1995 215
Unichem 1997 All workers
Table 4.3: Reduction of Workforce
(Source Internet 5)
Thus, the total payment on voluntary retirement schemes by firms like
Glaxo, Hoechst, Pfizer, Knoll Pharma, Rhone Poulenc, Park Davis, Smith
Kline Beecham, Duphar, Bayer etc. are more than Rs. 2000 million in the
last three financial years. The key aspect is that employment opportunities
in these units have been reduced gradually.
4.2.4 PRICES AND IMPACT ON SOCIAL WELFARE
Is it true to say that economic development is being achieved at the
expense of social welfare? On one hand deregulation and patent protection
are considered necessary encouragements for research and development,
inflow of foreign investment and overall economic development. At the same
time their immediate impact could be social upheaval, resulting from
increase in the price of essential drugs, and the lifting of price controls could
have a more serious impact on drug consumers. Recent market trend seem
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to confirm this, ''the price of Alludrox (an ant-acid) and Lanoxin (a cardio-
vascular) drug rose by 114% and 105% respectively after the new drug
policy was implemented" (Internet 6).
Poverty is widespread in India, according to Uma Kapila (2001), 15% of the
population is living below the poverty line, and around 20-30% live on or
slightly above the poverty line, which means that if drug prices swell to
about 20%, then 40-50% of the Indian population will no longer be able to
afford proper medication and health care for themselves. Is this what was
intended by WTO agreement and Uruguay round of talks or the so-called
'globalisation'? Well, the government will have to step in and put in place
policies for redistribution of this income generated in the economy, to
provide medical aid to people who no longer will be able to afford it once the
prices go up.
The international trade theories suggested that prices fall as a result of free
trade. However, in the case of Indian pharmaceutical industry the opposite
seems to hold that is higher drug prices after adhering to WTO and Uruguay
Round of trade negotiations. Well in that case, what will happens to the
vision of former Prime Minister Indira Gandi of providing health care to every
citizen of the country at affordable prices and that 'there will be no
profiteering from life and death'? It is believed that costs of medicines will
swell as a result of royalty payments and increased price for products
manufactured under license. Therefore, there is a implication for drug prices
going up due to patent protection as a consequence of WTO.
Looking at it from short-term point of view, yes some prices will go up but
not all, some in fact would go down. As we established in chapter 2 that
market forces, not intellectual property and trade barriers, drives prices.
Therefore, to combat market denomination, higher prices and monopolistic
trends, government would have to step in with reforms such as price
controls and mechanisms for fair redistribution of wealth benefiting all. It was
established in chapter two that in order to go the global route and be
successful in achieving overall growth, it is important for the government to
assume its role where needed, leaving rest to the market forces to correct
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itself. If prices go up in the future, the DPCO can regulate them to create
equilibrium. Moreover, market forces don't permit profiteering for too long.
Sooner or later, a cheaper competitor will break the monopoly. It is a myopic
view that multinationals will dominate the industry, as players are emerging
at all levels.
Another aspect of welfare is that competition generated by the MNCs will
improve the standard of health care system in India, making it better and
more efficient benefiting all.
4,3 IMPACT ON PUBLIC SECTOR DRUG COMPANIES
With the reduced role and function of the government under 'globalisation',
the public sector drug companies are faced with serious problems including
imminent closures. Public sector drug companies like Indian Drugs and
Pharmaceuticals Ltd. (IDPL), Hindustan Antibiotics Ltd. (HAL), Bengal
Chemicals and Pharmaceuticals Ltd. (BCPL), Bengal Immunity (BI) and
Smith Stanistreet Pharmaceuticals Ltd. (SSPL) played an important role in
the production of essential drugs at affordable prices. Under the
globalisation process the role of the public sector has been reduced.
Attempts have been made to either privatise or close them. The Penicillin
Plant in HAL, the biggest in the country, has been handed over to private
sector. Its Streptomycin plant also has been leased to a private company in
order to manufacture other drugs. IDPL, which has the biggest
pharmaceutical plant in Asia, has been shut down since 1996 due to the
lack of financial assistance from the government. The public sector drug
companies were supplying the raw materials to the small-scale sector
companies. Currently, these firms are facing difficulties in procuring raw
materials. Similar is the state of affairs of BCPL, B.1. and SSPL. These three
units were taken over by the government after they were made unprofitable
by the private owners. Proper utilisation of their capacity could not be made
due to lack of will on the part of the government, mismanagement at the
administrative level and high level corruption. It is not because of any
inherent weakness but due to the lack of political will, deliberate efforts to
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destroy them, corruption and mismanagement that these public sector units
have been rendered commercially unviable.
Furthermore, the numbers of workers engaged in these units have been
reduced drastically. When IDPL was established, it had more than 15,000
employees. At present, the number of employees is less than 7,000
(Internet 10).
With the pharmaceutical industry taking a leap towards biotechnology
development worldwide, only the public sector drug companies, with the
backing of the Central Government, could have faced the challenge
effectively from the MNCs in the new situation.
M..EYALUATING INPIAN PHARMACEUTICAL INpUSTRY AGAINST PORTERS
DIAMOND
With the use of the Porters Diamond it can be determined whether Indian
pharmaceutical industry has the required attributes to withstand international
competition to achieve international success.
According to Porter (Svend: 2001), four broad attributes of a nation shape
the environment in which homegrown firms compete and these attributes
promote or impede the creation of competitive advantage (see figure 4.2).
Determinant of National Competitive Advantage for the Indian
Pharmaceutical Industry: Porter's Diamond
~ Firm Strategy ~Structure, andRivalry
r
Factor






Figure 4.2: Determinant of National Competitive Advantage of Indian Pharmaceutical
Industry: Porter's Diamond
(Source: Svend: 2001)
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4.4.1 FACTOR ENDOWMENT
India has the natural resources and raw ingredients, which makes it self-
sufficient in manufacturing most of the bulk drugs and formulations. Apart
from the basic factors (such as natural resources, climate, location and
demographics), Indian pharmaceutical sector is endowed with well-
developed infrastructure, abundance in human intellectual capital and state
of the art research facilities. These elements are imperative for India's
success in the Pharma industry.
4.4.2 DEMAND CONDITIONS
It was stated by Porters (1995) as cited in Hill (2003) that home demand
plays a very vital role in upgrading the competitive advantage of a particular
industry because firms are more sensitive to the needs of their closest
consumers specifically their domestic consumers. Therefore, the nature of
local/ domestic demand is fundamental in terms of improving the quality and
encouraging innovation. Demand conditions in India are as such that it
motivates the manufacturers to introduce the latest drugs at the lowest
possible prices. Which has led to 'me too' drugs and today the market is
flooded with these kinds of drugs. It is not that the Indian pharmaceutical
sector or industries don't have the technical know how, or lacks research
capabilities, but the fact remains that due to governments past policies and
the drug price authorities, the people are accustomed to lower drug prices.
So, even though in India the demand for drugs and latest drugs is ever on
the rise, this factor alone doesn't encourage the manufacturers to produce
them, especially if they can easily copy them without having to invest in
research and development. However, the tables will turn, 'post 2005 patents
protection', the multinationals will enter the Indian market and the domestic
firms will have to comply with the patents, and it seems that in that scenario
the demand conditions will play a very significant role, encouraging
innovation and quality. Thus, increasing the competitive advantage of India,
which will allow Indian pharma firms to compete nationally and
internationally.
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4.4.3 RELATING AND SUPPORTING INDUSTRIES
As discussed in chapter 2, the third characteristic that provides national and
international competitive advantage is the presence of supporting or related
industry that is internationally competitive. Some of the relating and
supporting industries for the pharmaceuticals is, hospitals with well-
developed infrastructure, skilled and efficient doctors, widespread
pharmacies (distribution channel), efficient and innovative chemical
producing industries. These industries provide Indian pharmaceutical
industry with a competitive advantage. These industries provide a basis for
the success of pharmaceutical industry.
4.4.4 FIRM STRATEGY, STRUCTURE AND RIVALRY
According to Porters (Svend Hollensen: 2001), strategy, structure, and
rivalry of firms within a country is the fourth broad attribute responsible for
competitive advantage. In Indian pharmaceutical industry, vigorous rivalry
within the industry especially in the past three decades has encouraged
firms to look for ways to improve efficiency and quality, which makes them
better international competitors. This is illustrated by the increase in
international trade both in terms of exports and imports in the last couple of
years; exports have gone from Rs 3.050 million to Rs 6,6310 million in
1965-66 and 1999-2000 respectively. On the other hand imports have gone
up from Rs 8,200 million to Rs 3,4410 million in 1965-66 and 1999-2000
respectively (Internet 5).
4.5 CONCLUSION
At present, there is so much opportunity for the Indian pharmaceutical
industry, such as tapping on the generics market internationally and new
product innovation. This can provide Indian firms with a competitive
advantage. Other upcoming areas in pharmaceutical research are genomics
and biotechnology, where Indian firms can excel. In addition to this, free
trade regime will bring about increased trade, inflow of foreign investment
and MNCs. This will open new doors for the Indian firms in the form of
strategic alliances. Thus providing the domestic firms with the much need
financial and other resources to compete internationally.
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Similarly, government policies and regulations can improve national
advantage or can do the total opposite. On one hand deregulation and
patent protection are considered necessary for encouraging research and
development, inflow of foreign capital and overall economic development.
Looking at it from the other side of the coin, they are considered detrimental
with regards to social welfare leading to increase in prices of drugs and
unemployment. In this situation it is imperative for the government to reform
its policies and regulation in order to protect the social welfare. Changes in
government policies and regulations, and recommendations relating to
competition, strategic alliances and international competition will be
discussed in the next chapter.
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CHAPTER FIVE: RECOMMENDATIONS AND CONCLUSION
FOR THE INDIAN PHARMACEUTICAL INDUSTRY
5.1 INTRODUCTION
The liberalisation of the Indian economy is transforming the India
n
businesses as they begin to emerge from domestic markets and prepar
e
themselves for global competition. The Indian pharmaceutical industry is
a
prime example of an industry that is being forced to re-examine and re
-
evaluate its long-term strategy as it begins to open its borders to glob
al
trade.
The protectionist policies that India has implemented over the last thre
e
decades have had a significant impact on its pharmaceutical sector, whic
h
has resulted in the development of considerable expertise in revers
e
engineering of drugs. Consequently, the Indian pharmaceutical indust
ry
grew rapidly by developing inexpensive versions of several original drugs fo
r
the domestic market and eventually entered aggressively into th
e
international market with generic drugs, once the patents expired.
The present government is bringing out a bill to change the Indian patent a
ct
of 1970 in order to abide by the WTO liberalisation policies. It is believe
d
that the change in the act is not in the interest of the society at large, whic
h
will lead to price hike, job loss and worsen unemployment. According to th
e
industry sources it is also assumed that the patents have become an obje
ct
of businesses instead of development. Considering the wide gap
of
industrial and technological development between developed an
d
developing countries, monopoly rights through the patent system should n
ot
be allowed to the rich nations. Today the transnational companies and th
e
multinational companies of the rich nations are controlling 85% of th
e
patents. According to the world development report (1997), "Globalisation i
s
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hurting poor people, not just the poor countries, in this process poor
countries and poor people will become increasingly marginalized".
The question is why this pressure and hurry - the main aim is to impose
policies of WTO and to change the Indian Patent Act since MNCs need
more markets and are eyeing Asia which is the largest continent of the world
where 60% of the world population lives but contributes only 20% of the
world pharmaceuticals business. With a high rate of population growth it is
expected that the need of drugs will tremendously increase in the third world
countries including India in the next millennium. According to Confederation
of Indian industries (2002), India contributes 16.1 % of the world population,
but it produces only 1.2% of the world drug production. Therefore the foreign
firms are trying to have more control over the pharmaceutical markets of the
developing nations. Developed counties are backing their big companies to
capture markets in other countries even at the expense of the interest of
their own people.
5.2 RECOMMENDATIONS
However, the pharmaceutical industry will have to reassess their strategies
as they begin to step into a borderless world. At the same time the
government will have to revise its regulations and polices in order to create
a balance, so that everybody benefits in the long run. Therefore, the role of
the government would be to ensure that the pendulum doesn't swing to the
extreme right or extreme left but eventually, as the policies and regulations
come into play, the pendulum come to its middle position. Together with the
suggestions for the government, lets consider some recommendations for
the Pharmaceutical industry to survive the winds of liberalisation and help in
making India a global industrial base.
5.2.1 STRATEGIC ALLIANCES
In order to survive and create a place for itself in this era of globalisation,
Indian indigenous companies will have to tie up with the western companies
for global reach. The market is expected to become fiercely competitive in
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another five years time. This is expected to result in a spate of consolidation
moves in the form of mergers and acquisitions.
The Indian pharmaceutical companies should formulate strategic alliances
in the area of contract manufacturing, co-marketing and licensing. Strategic
alliances will assist companies to capitalise on each others strengths and
help Indian firms to gain access to financial resources and international
technology, for co-marketing and to enter international markets.
Consecutively, to leverage costs and increase market presence both in India
and globally, the coming years will see the takeover of medium and small
players by the large players. Domestic and multinational companies would
enter into alliances of all conceivable kinds like, technical, marketing,
licensing arrangements, and contract research and manufacturing. Strategic
alliances with the foreign players will also improve their distribution
channels, which will help the indigenous firms to strengthen their sales,
marketing and distribution network and penetrate international markets.
5.2.1.1 RESEARCH AND DEVELOPMENT
Research and development has always taken the back seat as far as Indian
pharmaceutical companies are concerned. In an attempt to stay competitive
in the future, they will have to refocus and invest in research and
development. This will help the Indian industries in developing new
molecules or strong reverse engineering skills to keep their product portfolio
young. In order to enhance R&D activities by the Indian companies, the
following steps should be undertaken:-
Increase cross border collaborative research
Increase funding for R&D
Create the necessary infrastructure for development of R&D work
in the country
Chapter Five g:~rn.t't't-...o_"'",,"":""' .... __ ..__ I' •
86 of 88
5.2.2 GENERIC MARKET
The global generic market presents substantial opportunities for Indian
pharma companies. In most European countries and U.S, the generics
sector is growing at a rapid pace as more and more branded products are
coming off patent protection. Therefore India has an opportunity to tap on
the global generic market and a well-developed domestic generic market to
support that.
The global market is transforming itself. Drugs that accounted for sales of
nearly $90 billion in 1995 will come off patents between the years 2002 and
2005. With generics priced at 15-25% of their patented precursors, the
generics market is believed to swell. The global market for generic drugs is
estimated at around $20 billion currently, and is expected to rise to $ 30
billion by 2000-2005 (Internet 8).
This increase represents a potential gain for Indian pharmaceutical
companies, as their generic products will now find increased opportunities in
the global marketplace. According to a recent study by the Indian Drug
Manufacturers Association, within the next 10 years, patents of most of the
world's top 100 drugs will expire and India is well positioned to capture the
opportunities presented by the generic market.
5.3 RECOMMENDATIONS FOR THE GOVERNMENT
Job loss, hike in prices and increasing unemployment are detrimental to the
social welfare of the country. So what is the solution to curb all of this?
Should the policy makers put in place barriers in order to discourage
multinationals from entering the domestic market? End all ties with the WTO
and consequently be left behind in the race of 'globalisation'? All these
measures can be adopted, but whether they are suitable and at the same
time feasible is the most important question. It is apparent, after discussions
about trade liberalisation and its impact on an economy that the above
measures, perhaps, would prove to be even more detrimental to the growth
and economic development. Eventually this will lead to more job losses,
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widespread unemployment, poverty and rise in inefficient and uncompetitive
industries.
Does this mean that we are caught in a vicious circle? Well the answer is
not really. Economies should realise two things, firstly, protectionist policy
can actually impede the growth prospects and secondly, government should
assume some responsibility to redistribute welfare and profit in order to
benefit the society at large. One milestone has been reached, and that is
doing away with the protectionist policies and liberalisation of the economy.
However, the second milestone is as difficult as the first one, and that is
government's role. The state should, therefore step in (not control) and put
in place policies for redistribution of the income generated in the economy
due to 'globalisation' to provide medical aid to people who no longer will be
able to afford it once there is a hike in prices. In addition to this, the
government will have to step in to create more jobs.
5.4 CONCLUSION
The liberalisation process and adherence to the WTO agreements will
probably help India to develop policies that are focused on attracting capital
from overseas, and making India a global industrial base. The inflows of
foreign direct investment and technology transfers will create an
environment for dynamic growth and increased competitiveness of Indian
industries. India is slowly moving into global markets and competing with
international quality standards and prices.
Issues such as poverty, unemployment and rising prices, seem a short run
phenomenon, which are part and parcel of trade liberalisation and can be
handled through sound government policies. If the government and the
Indian industries work in unison, economic growth, prosperity, social
welfare, poverty reduction, and all that globalisation promises, can be
achieved and sustained over the long run.
Privatisation, along with trade liberalisation needs to be part of a more
comprehensive program, which entails creating jobs in tandem with the
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inevitable job destruction. Macroeconomic policies including low interest
rates that help create jobs have to be put in place.
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